US20040224960A1 - Pharmaceutical compositions and methods for their use - Google Patents
Pharmaceutical compositions and methods for their use Download PDFInfo
- Publication number
- US20040224960A1 US20040224960A1 US10/783,117 US78311704A US2004224960A1 US 20040224960 A1 US20040224960 A1 US 20040224960A1 US 78311704 A US78311704 A US 78311704A US 2004224960 A1 US2004224960 A1 US 2004224960A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- ethyl
- hydroxy
- cyclopentyl
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 263
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims abstract description 81
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims abstract description 80
- 241000124008 Mammalia Species 0.000 claims abstract description 42
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 26
- 230000003247 decreasing effect Effects 0.000 claims abstract description 12
- 230000004060 metabolic process Effects 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 83
- 150000003839 salts Chemical class 0.000 claims description 82
- 239000012453 solvate Substances 0.000 claims description 60
- -1 bupronolol Chemical compound 0.000 claims description 42
- XPRDGKCNHYYXEJ-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC=C(C(C)(C)C#N)C(F)=C1 XPRDGKCNHYYXEJ-UHFFFAOYSA-N 0.000 claims description 36
- NYMOMHNTEZVNLN-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3h-pyran-2-yl]ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound C1C(O)=C(CC2=NN3C=CC=NC3=N2)C(=O)OC1(C1CCCC1)CCC(C=C1F)=CC=C1C1(C#N)CC1 NYMOMHNTEZVNLN-UHFFFAOYSA-N 0.000 claims description 34
- QIZHUTLNVCKLQD-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC(C=C1F)=CC=C1C1(C#N)CC1 QIZHUTLNVCKLQD-UHFFFAOYSA-N 0.000 claims description 33
- URWAQHBJFIHLHY-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(F)=C(C(C)(C)C#N)C(F)=C1 URWAQHBJFIHLHY-UHFFFAOYSA-N 0.000 claims description 33
- OBCKRNZZGMAHQG-UHFFFAOYSA-N 2-[4-[2-[5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(Cl)C=NC3=N2)=C(O)C1 OBCKRNZZGMAHQG-UHFFFAOYSA-N 0.000 claims description 33
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 27
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 27
- 239000011737 fluorine Substances 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- SGSKJWYJGCQGSG-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC(C=C1F)=CC=C1C1(C#N)CC1 SGSKJWYJGCQGSG-UHFFFAOYSA-N 0.000 claims description 25
- HLCKTRPHZPLULD-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC=C(C(C)(C)C#N)C(F)=C1 HLCKTRPHZPLULD-UHFFFAOYSA-N 0.000 claims description 24
- ACQWOCBAUUSACB-UHFFFAOYSA-N 2-[4-[2-[5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=C(F)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(Cl)C=NC3=N2)=C(O)C1 ACQWOCBAUUSACB-UHFFFAOYSA-N 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- UIFRJOFUXVWMCY-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=CC=NC3=N2)=C(O)C1 UIFRJOFUXVWMCY-UHFFFAOYSA-N 0.000 claims description 14
- 102000001708 Protein Isoforms Human genes 0.000 claims description 13
- 108010029485 Protein Isoforms Proteins 0.000 claims description 13
- CTUFIDTYIQVNBF-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]cyclopropane-1-carbonitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC(C=C1F)=CC(F)=C1C1(C#N)CC1 CTUFIDTYIQVNBF-UHFFFAOYSA-N 0.000 claims description 12
- CHLULEVMRJYVDI-UHFFFAOYSA-N 1-[4-[2-[5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound C1C(O)=C(CC2=NN3C=C(Cl)C=NC3=N2)C(=O)OC1(C1CCCC1)CCC(C=C1F)=CC=C1C1(C#N)CC1 CHLULEVMRJYVDI-UHFFFAOYSA-N 0.000 claims description 12
- OUZYDPGBHPOMKF-UHFFFAOYSA-N 2-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound ClC1=C(O)C(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 OUZYDPGBHPOMKF-UHFFFAOYSA-N 0.000 claims description 12
- XVWAACALGSGHOT-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)C(CC=2N=C3C=CC=CN3C=2)=C(O)C1 XVWAACALGSGHOT-UHFFFAOYSA-N 0.000 claims description 12
- CQDZQTZXLHKKNS-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(5-methyl-1h-imidazol-4-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound N1=CNC(CC=2C(OC(CCC=3C=C(F)C(=CC=3)C(C)(C)C#N)(CC=2O)C2CCCC2)=O)=C1C CQDZQTZXLHKKNS-UHFFFAOYSA-N 0.000 claims description 12
- UTWDZLPUNCOBIS-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile Chemical compound COC1=CC(C(C)(C)C#N)=C(F)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(C)C=NC3=N2)=C(O)C1 UTWDZLPUNCOBIS-UHFFFAOYSA-N 0.000 claims description 12
- NUNRIZMOZWCIDP-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=C(F)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=CC=NC3=N2)=C(O)C1 NUNRIZMOZWCIDP-UHFFFAOYSA-N 0.000 claims description 12
- WPFZUBJLEPQDLE-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-5-[(6-ethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound N=1N2C=C(CC)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(F)=C(C(C)(C)C#N)C(F)=C1 WPFZUBJLEPQDLE-UHFFFAOYSA-N 0.000 claims description 12
- CLRHDXOXRCWEDY-UHFFFAOYSA-N 2-[4-[[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]methoxy]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)COC1=CC=C(C(C)(C)C#N)C(F)=C1 CLRHDXOXRCWEDY-UHFFFAOYSA-N 0.000 claims description 12
- IIWBURXNZZIWRO-UHFFFAOYSA-N 2-[4-[[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]methoxy]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)COC1=CC=C(C(C)(C)C#N)C(F)=C1 IIWBURXNZZIWRO-UHFFFAOYSA-N 0.000 claims description 12
- QKCIIUREMDXCJJ-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=C(O)C(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 QKCIIUREMDXCJJ-UHFFFAOYSA-N 0.000 claims description 12
- BHMNXWQULUUGCN-UHFFFAOYSA-N 5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-2-[2-[3-fluoro-4-(2-hydroxypropan-2-yl)phenyl]ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=C(F)C(C(C)(O)C)=CC=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(Cl)C=NC3=N2)=C(O)C1 BHMNXWQULUUGCN-UHFFFAOYSA-N 0.000 claims description 12
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 12
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 12
- XAHKNGMYDIGWLG-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(F)=C(C(C)(C)C#N)C(F)=C1 XAHKNGMYDIGWLG-UHFFFAOYSA-N 0.000 claims description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 10
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 10
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 10
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 10
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical group C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 claims description 8
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 7
- 229960001985 dextromethorphan Drugs 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims description 5
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 5
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims description 5
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 5
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 5
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 5
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 claims description 5
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 5
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 5
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 5
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims description 5
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims description 5
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims description 5
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 5
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 5
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 5
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 5
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 5
- 229960002781 bisoprolol Drugs 0.000 claims description 5
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- 229960000830 captopril Drugs 0.000 claims description 5
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 5
- 229960003291 chlorphenamine Drugs 0.000 claims description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001076 chlorpromazine Drugs 0.000 claims description 5
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 5
- 229960004588 cilostazol Drugs 0.000 claims description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 5
- 229960001653 citalopram Drugs 0.000 claims description 5
- 229960004606 clomipramine Drugs 0.000 claims description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 5
- 229960004170 clozapine Drugs 0.000 claims description 5
- 229960004126 codeine Drugs 0.000 claims description 5
- 229960003914 desipramine Drugs 0.000 claims description 5
- 229960004597 dexfenfluramine Drugs 0.000 claims description 5
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 5
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 5
- 229960005426 doxepin Drugs 0.000 claims description 5
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001142 encainide Drugs 0.000 claims description 5
- 229960004578 ethylmorphine Drugs 0.000 claims description 5
- 229960001582 fenfluramine Drugs 0.000 claims description 5
- 229960000449 flecainide Drugs 0.000 claims description 5
- 229960002464 fluoxetine Drugs 0.000 claims description 5
- 229960002690 fluphenazine Drugs 0.000 claims description 5
- 229960003878 haloperidol Drugs 0.000 claims description 5
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 5
- 229960000240 hydrocodone Drugs 0.000 claims description 5
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004801 imipramine Drugs 0.000 claims description 5
- 229960002056 indoramin Drugs 0.000 claims description 5
- 229960001632 labetalol Drugs 0.000 claims description 5
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 claims description 5
- 229960004194 lidocaine Drugs 0.000 claims description 5
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 5
- 229960003088 loratadine Drugs 0.000 claims description 5
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 5
- 229960004090 maprotiline Drugs 0.000 claims description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
- 229960001252 methamphetamine Drugs 0.000 claims description 5
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 5
- 229960002237 metoprolol Drugs 0.000 claims description 5
- 229960003404 mexiletine Drugs 0.000 claims description 5
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 5
- 229960005181 morphine Drugs 0.000 claims description 5
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 5
- 229960001800 nefazodone Drugs 0.000 claims description 5
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 5
- 229960000884 nelfinavir Drugs 0.000 claims description 5
- 229960001158 nortriptyline Drugs 0.000 claims description 5
- 229960000381 omeprazole Drugs 0.000 claims description 5
- 229960005343 ondansetron Drugs 0.000 claims description 5
- 229960002085 oxycodone Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 229960002296 paroxetine Drugs 0.000 claims description 5
- 229960000762 perphenazine Drugs 0.000 claims description 5
- 229960000482 pethidine Drugs 0.000 claims description 5
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 5
- 229960003243 phenformin Drugs 0.000 claims description 5
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 claims description 5
- 229960000203 propafenone Drugs 0.000 claims description 5
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 5
- 229960001404 quinidine Drugs 0.000 claims description 5
- 229930002330 retinoic acid Natural products 0.000 claims description 5
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 5
- 229960001534 risperidone Drugs 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- 229960001603 tamoxifen Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229960003604 testosterone Drugs 0.000 claims description 5
- 229960004605 timolol Drugs 0.000 claims description 5
- 229960004380 tramadol Drugs 0.000 claims description 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 5
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 5
- 229960003991 trazodone Drugs 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 claims description 5
- 229960002341 trifluperidol Drugs 0.000 claims description 5
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 5
- 229960002431 trimipramine Drugs 0.000 claims description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004688 venlafaxine Drugs 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 5
- PTJADDMMFYXMMG-LJQANCHMSA-N (1r)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-3h-2-benzofuran-5-carbonitrile Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCNC)=CC=C(F)C=C1 PTJADDMMFYXMMG-LJQANCHMSA-N 0.000 claims description 4
- SSEBTPPFLLCUMN-CYBMUJFWSA-N (1r)-2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol Chemical compound CCC1=CC=CC2=C1OC([C@H](O)CNC(C)(C)C)=C2 SSEBTPPFLLCUMN-CYBMUJFWSA-N 0.000 claims description 4
- XWWMJXAFEKOGFK-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-2-yl)ethanamine Chemical compound COC1=CC=C2NC(CCN)=CC2=C1 XWWMJXAFEKOGFK-UHFFFAOYSA-N 0.000 claims description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 4
- 229930008564 C01BA04 - Sparteine Natural products 0.000 claims description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 4
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 4
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 4
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 claims description 4
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 claims description 4
- 229960002213 alprenolol Drugs 0.000 claims description 4
- HFQMYSHATTXRTC-JTQLQIEISA-N amiflamine Chemical compound C[C@H](N)CC1=CC=C(N(C)C)C=C1C HFQMYSHATTXRTC-JTQLQIEISA-N 0.000 claims description 4
- 229950004939 amiflamine Drugs 0.000 claims description 4
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004957 aprindine Drugs 0.000 claims description 4
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 4
- 229960002430 atomoxetine Drugs 0.000 claims description 4
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims description 4
- 229950004068 brofaromine Drugs 0.000 claims description 4
- 229950006886 bufuralol Drugs 0.000 claims description 4
- VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 claims description 4
- 229950008581 bunitrolol Drugs 0.000 claims description 4
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 4
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 claims description 4
- 229960000876 cinnarizine Drugs 0.000 claims description 4
- JWPGJSVJDAJRLW-UHFFFAOYSA-N debrisoquin Chemical compound C1=CC=C2CN(C(=N)N)CCC2=C1 JWPGJSVJDAJRLW-UHFFFAOYSA-N 0.000 claims description 4
- 229960004096 debrisoquine Drugs 0.000 claims description 4
- 229960003413 dolasetron Drugs 0.000 claims description 4
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 4
- 229960000326 flunarizine Drugs 0.000 claims description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 4
- 229960004038 fluvoxamine Drugs 0.000 claims description 4
- HIUVKVDQFXDZHU-UHFFFAOYSA-N guanoxan Chemical compound C1=CC=C2OC(CNC(=N)N)COC2=C1 HIUVKVDQFXDZHU-UHFFFAOYSA-N 0.000 claims description 4
- 229960000760 guanoxan Drugs 0.000 claims description 4
- OEHAYUOVELTAPG-UHFFFAOYSA-N methoxyphenamine Chemical compound CNC(C)CC1=CC=CC=C1OC OEHAYUOVELTAPG-UHFFFAOYSA-N 0.000 claims description 4
- 229960005405 methoxyphenamine Drugs 0.000 claims description 4
- 229960003955 mianserin Drugs 0.000 claims description 4
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004758 minaprine Drugs 0.000 claims description 4
- REIPDEIPEOYEDO-UHFFFAOYSA-N n-methoxy-1-phenylpropan-2-amine Chemical compound CONC(C)CC1=CC=CC=C1 REIPDEIPEOYEDO-UHFFFAOYSA-N 0.000 claims description 4
- HKOIXWVRNLGFOR-KOFBORESSA-N norcodeine Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4 HKOIXWVRNLGFOR-KOFBORESSA-N 0.000 claims description 4
- 229950004392 norcodeine Drugs 0.000 claims description 4
- HKOIXWVRNLGFOR-UHFFFAOYSA-N norcodeine Natural products O1C2C(O)C=CC3C4CC5=CC=C(OC)C1=C5C23CCN4 HKOIXWVRNLGFOR-UHFFFAOYSA-N 0.000 claims description 4
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims description 4
- 229960000989 perhexiline Drugs 0.000 claims description 4
- 229960004215 prajmaline Drugs 0.000 claims description 4
- UAUHEPXILIZYCU-ALHOSYKFSA-N prajmalium Chemical compound CN([C@H]12)C3=CC=CC=C3[C@]11C[C@@H]3[N@@+](CCC)([C@@H]([C@H]4CC)O)[C@H]2C[C@@H]4[C@@H]3[C@H]1O UAUHEPXILIZYCU-ALHOSYKFSA-N 0.000 claims description 4
- 229960003910 promethazine Drugs 0.000 claims description 4
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 claims description 4
- 229960001945 sparteine Drugs 0.000 claims description 4
- 229960002784 thioridazine Drugs 0.000 claims description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 4
- 229960004045 tolterodine Drugs 0.000 claims description 4
- 229960003688 tropisetron Drugs 0.000 claims description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 4
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims description 4
- 229960004141 zuclopenthixol Drugs 0.000 claims description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims 9
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 3
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 144
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 142
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 120
- 238000005160 1H NMR spectroscopy Methods 0.000 description 73
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
- 235000019439 ethyl acetate Nutrition 0.000 description 64
- 239000000243 solution Substances 0.000 description 64
- 239000000047 product Substances 0.000 description 61
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 47
- 239000003921 oil Substances 0.000 description 37
- 235000019198 oils Nutrition 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000007787 solid Substances 0.000 description 30
- 125000004093 cyano group Chemical group *C#N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- 239000007832 Na2SO4 Substances 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 25
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 23
- 238000003818 flash chromatography Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 17
- KDHRPFWKGKTWMM-UHFFFAOYSA-N 2-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)CC(=O)C1 KDHRPFWKGKTWMM-UHFFFAOYSA-N 0.000 description 16
- WSPTZMRMBBUVSH-UHFFFAOYSA-N 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde Chemical compound N1=C(C)C=C(C)N2N=C(C=O)N=C21 WSPTZMRMBBUVSH-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- WPCTXASXKDFYBT-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(Br)C=C1F WPCTXASXKDFYBT-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- SEDKPQNOXDKIDR-UHFFFAOYSA-N 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde Chemical compound C1=C(C)C=NC2=NC(C=O)=NN21 SEDKPQNOXDKIDR-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- YEORFXLRFIQXGI-UHFFFAOYSA-N 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-1,3-dioxin-4-one Chemical compound O1C(C)(C)OC(=O)C=C1CC(O)(C#C)C1CCCC1 YEORFXLRFIQXGI-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000003821 enantio-separation Methods 0.000 description 9
- QLASQEZPJFNZQC-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)acetonitrile Chemical compound FC1=CC(Br)=CC=C1CC#N QLASQEZPJFNZQC-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- NKLZTOQYZRGDGQ-UHFFFAOYSA-N 2-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1C#CC(O)(C1CCCC1)CC1=CC(=O)OC(C)(C)O1 NKLZTOQYZRGDGQ-UHFFFAOYSA-N 0.000 description 7
- RQVBODKONRTYBP-UHFFFAOYSA-N 6-chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde Chemical group C1=C(Cl)C=NC2=NC(C=O)=NN21 RQVBODKONRTYBP-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- 238000004808 supercritical fluid chromatography Methods 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- DVELQFRMBYQOFZ-UHFFFAOYSA-N 1-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical group C=1C=C(C2(CC2)C#N)C(F)=CC=1CCC1(C2CCCC2)CC(=O)CC(=O)O1 DVELQFRMBYQOFZ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- WQWSMVWRGAFPJX-UHFFFAOYSA-N (3-amino-1h-1,2,4-triazol-5-yl)methanol Chemical compound NC1=NNC(CO)=N1 WQWSMVWRGAFPJX-UHFFFAOYSA-N 0.000 description 5
- RLURHAMJMNWELO-UHFFFAOYSA-N (6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol Chemical compound N1=CC(Cl)=CN2N=C(CO)N=C21 RLURHAMJMNWELO-UHFFFAOYSA-N 0.000 description 5
- KXFXYWKCJXBULR-UHFFFAOYSA-N 2-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=C(F)C=C1CCC1(C2CCCC2)OC(=O)CC(=O)C1 KXFXYWKCJXBULR-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RRJISOYOTBASPN-UHFFFAOYSA-N 1-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2,6-difluorophenyl]cyclopropane-1-carbonitrile Chemical group C=1C(F)=C(C2(CC2)C#N)C(F)=CC=1CCC1(C2CCCC2)CC(=O)CC(=O)O1 RRJISOYOTBASPN-UHFFFAOYSA-N 0.000 description 4
- BLIDEFNAYHTSFH-UHFFFAOYSA-N 1-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2-fluorophenyl]cyclobutane-1-carbonitrile Chemical compound C=1C=C(C2(CCC2)C#N)C(F)=CC=1CCC1(C2CCCC2)CC(=O)CC(=O)O1 BLIDEFNAYHTSFH-UHFFFAOYSA-N 0.000 description 4
- VUWUUFWCHYQQQX-UHFFFAOYSA-N 1-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound O1C(C)(C)OC(=O)C=C1CC(O)(C1CCCC1)C#CC1=CC=C(C2(CC2)C#N)C(F)=C1 VUWUUFWCHYQQQX-UHFFFAOYSA-N 0.000 description 4
- LAQFPQSYKMWFAW-UHFFFAOYSA-N 2-(4-bromo-2,6-difluorophenyl)acetonitrile Chemical compound FC1=CC(Br)=CC(F)=C1CC#N LAQFPQSYKMWFAW-UHFFFAOYSA-N 0.000 description 4
- CCWCTVRHFBDISJ-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)propan-2-ol Chemical compound CC(C)(O)C1=CC=C(Br)C=C1F CCWCTVRHFBDISJ-UHFFFAOYSA-N 0.000 description 4
- ZFKKUSWQWNEYCQ-UHFFFAOYSA-N 2-[4-[(2-cyclopentyl-4,6-dioxooxan-2-yl)methoxy]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1OCC1(C2CCCC2)OC(=O)CC(=O)C1 ZFKKUSWQWNEYCQ-UHFFFAOYSA-N 0.000 description 4
- GXIVPXOMNFBXJK-UHFFFAOYSA-N 3-[3-chloro-5-ethyl-4-(2-methoxyethoxymethoxy)phenyl]-1-cyclopentylpropan-1-one Chemical compound ClC1=C(OCOCCOC)C(CC)=CC(CCC(=O)C2CCCC2)=C1 GXIVPXOMNFBXJK-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- QLNVNDQNGQOBMA-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde Chemical compound N1=CC=CN2N=C(C=O)N=C21 QLNVNDQNGQOBMA-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- CVYGJOWQSXNUFW-UHFFFAOYSA-N (4-bromo-2-ethylphenyl) acetate Chemical compound CCC1=CC(Br)=CC=C1OC(C)=O CVYGJOWQSXNUFW-UHFFFAOYSA-N 0.000 description 3
- YZOGHNYIPBLBAM-UHFFFAOYSA-N (4-bromo-2-fluoro-5-methoxyphenyl)methanol Chemical compound COC1=CC(CO)=C(F)C=C1Br YZOGHNYIPBLBAM-UHFFFAOYSA-N 0.000 description 3
- OFJWBDBTRYHQJS-UHFFFAOYSA-N (6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol Chemical compound C1=C(C)C=NC2=NC(CO)=NN21 OFJWBDBTRYHQJS-UHFFFAOYSA-N 0.000 description 3
- 0 *ICc1cccc(**C[C@@](CC(O)=C2Cc3n[n](cccn4)c4n3)(C3CCCC3)OC2=O)c1 Chemical compound *ICc1cccc(**C[C@@](CC(O)=C2Cc3n[n](cccn4)c4n3)(C3CCCC3)OC2=O)c1 0.000 description 3
- UCOCUNWNHVTRDH-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)cyclobutane-1-carbonitrile Chemical compound FC1=CC(Br)=CC=C1C1(C#N)CCC1 UCOCUNWNHVTRDH-UHFFFAOYSA-N 0.000 description 3
- FLVJVGSVWLFBRZ-UHFFFAOYSA-N 1-(4-bromo-2-fluorophenyl)cyclopropane-1-carbonitrile Chemical compound FC1=CC(Br)=CC=C1C1(C#N)CC1 FLVJVGSVWLFBRZ-UHFFFAOYSA-N 0.000 description 3
- RSKOQKREZUXMEO-UHFFFAOYSA-N 1-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl]cyclobutane-1-carbonitrile Chemical compound O1C(C)(C)OC(=O)C=C1CC(O)(C1CCCC1)C#CC1=CC=C(C2(CCC2)C#N)C(F)=C1 RSKOQKREZUXMEO-UHFFFAOYSA-N 0.000 description 3
- RERBYFGUGFDVEX-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)-5-fluoro-2-methoxybenzene Chemical compound COC1=CC(CBr)=C(F)C=C1Br RERBYFGUGFDVEX-UHFFFAOYSA-N 0.000 description 3
- COLJQOWPCREOCG-UHFFFAOYSA-N 1-cyclopentyl-3-[3-fluoro-4-(2-hydroxypropan-2-yl)phenyl]propan-1-one Chemical compound C1=C(F)C(C(C)(O)C)=CC=C1CCC(=O)C1CCCC1 COLJQOWPCREOCG-UHFFFAOYSA-N 0.000 description 3
- SOOKTDLBGCXLGH-UHFFFAOYSA-N 2-(2-fluoro-4-hydroxyphenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(O)C=C1F SOOKTDLBGCXLGH-UHFFFAOYSA-N 0.000 description 3
- HVUUIRMIMFXUMJ-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenyl)-2-methylpropanenitrile Chemical compound COC1=CC=C(C(C)(C)C#N)C(F)=C1 HVUUIRMIMFXUMJ-UHFFFAOYSA-N 0.000 description 3
- OKPZYRPNHFQVMZ-UHFFFAOYSA-N 2-(2-fluoro-4-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C(F)=C1 OKPZYRPNHFQVMZ-UHFFFAOYSA-N 0.000 description 3
- YDBQIRCLAKUATF-UHFFFAOYSA-N 2-(4-bromo-2,6-difluorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=C(F)C=C(Br)C=C1F YDBQIRCLAKUATF-UHFFFAOYSA-N 0.000 description 3
- GBEZPEXHBNCIOD-UHFFFAOYSA-N 2-[4-(2-cyclopentyl-2-oxoethoxy)-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1OCC(=O)C1CCCC1 GBEZPEXHBNCIOD-UHFFFAOYSA-N 0.000 description 3
- VXEVKLDMSVRWQN-UHFFFAOYSA-N 2-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile Chemical compound COC1=CC(C(C)(C)C#N)=C(F)C=C1C#CC(O)(C1CCCC1)CC1=CC(=O)OC(C)(C)O1 VXEVKLDMSVRWQN-UHFFFAOYSA-N 0.000 description 3
- XMHNLZXYPAULDF-UHFFFAOYSA-N 4-bromo-1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1CBr XMHNLZXYPAULDF-UHFFFAOYSA-N 0.000 description 3
- ZINXHZZZNUPVRH-UHFFFAOYSA-N 4-bromo-2-chloro-6-ethylphenol Chemical compound CCC1=CC(Br)=CC(Cl)=C1O ZINXHZZZNUPVRH-UHFFFAOYSA-N 0.000 description 3
- MAAADQMBQYSOOG-UHFFFAOYSA-N 4-bromo-2-ethylphenol Chemical compound CCC1=CC(Br)=CC=C1O MAAADQMBQYSOOG-UHFFFAOYSA-N 0.000 description 3
- TWHBNRXZMJJLJO-UHFFFAOYSA-N 4-bromo-2-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=C(F)C=C1Br TWHBNRXZMJJLJO-UHFFFAOYSA-N 0.000 description 3
- VKTZDDCOYIMMDI-UHFFFAOYSA-N 5-bromo-1-chloro-3-ethyl-2-(2-methoxyethoxymethoxy)benzene Chemical compound CCC1=CC(Br)=CC(Cl)=C1OCOCCOC VKTZDDCOYIMMDI-UHFFFAOYSA-N 0.000 description 3
- VSKMLLGUWKLTQV-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)-1,3-difluorobenzene Chemical compound FC1=CC(Br)=CC(F)=C1CBr VSKMLLGUWKLTQV-UHFFFAOYSA-N 0.000 description 3
- VZHSTISFJQEOBN-UHFFFAOYSA-N 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyloxane-2,4-dione Chemical group ClC1=C(O)C(CC)=CC(CCC2(OC(=O)CC(=O)C2)C2CCCC2)=C1 VZHSTISFJQEOBN-UHFFFAOYSA-N 0.000 description 3
- NACQJCGXLZUZFL-UHFFFAOYSA-N 6-[2-[3-chloro-5-ethyl-4-(2-methoxyethoxymethoxy)phenyl]ethyl]-6-cyclopentyloxane-2,4-dione Chemical compound ClC1=C(OCOCCOC)C(CC)=CC(CCC2(OC(=O)CC(=O)C2)C2CCCC2)=C1 NACQJCGXLZUZFL-UHFFFAOYSA-N 0.000 description 3
- KUULEMYIWOJJSF-UHFFFAOYSA-N 6-cyclopentyl-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]oxane-2,4-dione Chemical group C1=C(O)C(CC)=CC(CCC2(OC(=O)CC(=O)C2)C2CCCC2)=C1 KUULEMYIWOJJSF-UHFFFAOYSA-N 0.000 description 3
- JBMIKOMKXSMSID-UHFFFAOYSA-N 6-cyclopentyl-6-[2-[3-fluoro-4-(2-hydroxypropan-2-yl)phenyl]ethyl]oxane-2,4-dione Chemical group C1=C(F)C(C(C)(O)C)=CC=C1CCC1(C2CCCC2)OC(=O)CC(=O)C1 JBMIKOMKXSMSID-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- BSYMHJJIFFEKLU-UHFFFAOYSA-N [4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]-2-ethylphenyl] acetate Chemical compound C1=C(OC(C)=O)C(CC)=CC(CCC2(OC(=O)CC(=O)C2)C2CCCC2)=C1 BSYMHJJIFFEKLU-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- QKKKBOZQZHBENG-UHFFFAOYSA-N imidazo[1,2-a]pyridine-2-carbaldehyde Chemical compound C1=CC=CC2=NC(C=O)=CN21 QKKKBOZQZHBENG-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- SHYHYVCNCNAWHV-UHFFFAOYSA-N (5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol Chemical compound N1=C(C)C=C(C)N2N=C(CO)N=C21 SHYHYVCNCNAWHV-UHFFFAOYSA-N 0.000 description 2
- AZNRWSPSFFMYGO-UHFFFAOYSA-N (6-ethenyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol Chemical compound N1=CC(C=C)=CN2N=C(CO)N=C21 AZNRWSPSFFMYGO-UHFFFAOYSA-N 0.000 description 2
- KDOAHVPFGIYCEU-AATRIKPKSA-N (e)-3-ethoxy-2-methylprop-2-enal Chemical compound CCO\C=C(/C)C=O KDOAHVPFGIYCEU-AATRIKPKSA-N 0.000 description 2
- BCNLTCJFKDBRKP-UHFFFAOYSA-N 1-(4-bromo-2,6-difluorophenyl)cyclopropane-1-carbonitrile Chemical compound FC1=CC(Br)=CC(F)=C1C1(C#N)CC1 BCNLTCJFKDBRKP-UHFFFAOYSA-N 0.000 description 2
- PKASKJTXIIPRME-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3h-pyran-2-yl]ethyl]-2-fluorophenyl]cyclobutane-1-carbonitrile Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC(C=C1F)=CC=C1C1(C#N)CCC1 PKASKJTXIIPRME-UHFFFAOYSA-N 0.000 description 2
- LWRKNHGYEUVPAT-UHFFFAOYSA-N 1-[4-[2-[5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4,6-dioxooxan-2-yl]ethyl]-2-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound C=1C=C(C2(CC2)C#N)C(F)=CC=1CCC1(OC(=O)C(CC2=NN3C=C(Cl)C=NC3=N2)C(=O)C1)C1CCCC1 LWRKNHGYEUVPAT-UHFFFAOYSA-N 0.000 description 2
- NTDDZKDTFPAXDH-UHFFFAOYSA-N 1-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2,6-difluorophenyl]cyclopropane-1-carbonitrile Chemical compound O1C(C)(C)OC(=O)C=C1CC(O)(C1CCCC1)C#CC1=CC(F)=C(C2(CC2)C#N)C(F)=C1 NTDDZKDTFPAXDH-UHFFFAOYSA-N 0.000 description 2
- ONUDNHNDLANEQQ-UHFFFAOYSA-N 1-cyclopentylprop-2-en-1-ol Chemical compound C=CC(O)C1CCCC1 ONUDNHNDLANEQQ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QEQOTADQVOVHJK-UHFFFAOYSA-N 2-(4-bromo-2-fluoro-5-methoxyphenyl)-2-methylpropanenitrile Chemical compound COC1=CC(C(C)(C)C#N)=C(F)C=C1Br QEQOTADQVOVHJK-UHFFFAOYSA-N 0.000 description 2
- AKLKJYJPXFQLIK-UHFFFAOYSA-N 2-(4-bromo-2-fluoro-5-methoxyphenyl)acetonitrile Chemical compound COC1=CC(CC#N)=C(F)C=C1Br AKLKJYJPXFQLIK-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LBYCGXPODHOHOV-UHFFFAOYSA-N 2-[4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3h-pyran-2-yl)ethyl]-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile Chemical group COC1=CC(C(C)(C)C#N)=C(F)C=C1CCC1(C2CCCC2)OC(=O)C=C(O)C1 LBYCGXPODHOHOV-UHFFFAOYSA-N 0.000 description 2
- TWDSJPZEAXRDOK-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-4,6-dioxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)oxan-2-yl]ethyl]-2-fluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=CC=NC3=N2)C(=O)C1 TWDSJPZEAXRDOK-UHFFFAOYSA-N 0.000 description 2
- UHNNVYAQSJMKRW-UHFFFAOYSA-N 2-[4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)-3-hydroxybut-1-ynyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=C(F)C=C1C#CC(O)(C1CCCC1)CC1=CC(=O)OC(C)(C)O1 UHNNVYAQSJMKRW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- XLKPUHFEQXPMCQ-UHFFFAOYSA-N 2-o-[2-cyclopentyl-1-(2,2-dimethyl-6-oxo-1,3-dioxin-4-yl)but-3-yn-2-yl] 1-o-ethyl oxalate Chemical compound C1CCCC1C(OC(=O)C(=O)OCC)(C#C)CC1=CC(=O)OC(C)(C)O1 XLKPUHFEQXPMCQ-UHFFFAOYSA-N 0.000 description 2
- QGOYOHVXVJHERE-UHFFFAOYSA-N 6-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde Chemical compound C1=C(CC)C=NC2=NC(C=O)=NN21 QGOYOHVXVJHERE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- DZCZHQMWXFXGDR-UHFFFAOYSA-N C.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)=N\N12 Chemical compound C.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)=N\N12 DZCZHQMWXFXGDR-UHFFFAOYSA-N 0.000 description 2
- WBBXQTVEKDBGJC-UHFFFAOYSA-N C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC(F)=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 Chemical compound C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC(F)=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 WBBXQTVEKDBGJC-UHFFFAOYSA-N 0.000 description 2
- YKOUJLIXXXMRAH-UHFFFAOYSA-N C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 Chemical compound C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 YKOUJLIXXXMRAH-UHFFFAOYSA-N 0.000 description 2
- MXTGRNLMMLFKDS-UHFFFAOYSA-N C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC=C(C5(C#N)CC5)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 Chemical compound C.CC1=CN2/N=C(CC3=C(O)CC(CCC4=CC=C(C5(C#N)CC5)C(F)=C4)(C4CCCC4)OC3=O)\N=C/2N=C1 MXTGRNLMMLFKDS-UHFFFAOYSA-N 0.000 description 2
- YSOHXPVYWCILJS-UHFFFAOYSA-N C.N#CC1(C2=CC=C(CCC3(C4CCCC4)CC(O)=C(CC4=N/N5C=CC=N\C5=N\4)C(=O)O3)C=C2F)CC1 Chemical compound C.N#CC1(C2=CC=C(CCC3(C4CCCC4)CC(O)=C(CC4=N/N5C=CC=N\C5=N\4)C(=O)O3)C=C2F)CC1 YSOHXPVYWCILJS-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LSRHFWSNUFIKER-UHFFFAOYSA-N (4-bromo-2,6-difluorophenyl)methanol Chemical compound OCC1=C(F)C=C(Br)C=C1F LSRHFWSNUFIKER-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- OTXHZHQQWQTQMW-UHFFFAOYSA-N (diaminomethylideneamino)azanium;hydrogen carbonate Chemical compound OC([O-])=O.N[NH2+]C(N)=N OTXHZHQQWQTQMW-UHFFFAOYSA-N 0.000 description 1
- XJQSLJZYZFSHAI-DUXPYHPUSA-N (e)-3-methoxyprop-2-enal Chemical group CO\C=C\C=O XJQSLJZYZFSHAI-DUXPYHPUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- HQCCNFFIOWYINW-UHFFFAOYSA-N 1-(5-bromo-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Br)=CC=C1O HQCCNFFIOWYINW-UHFFFAOYSA-N 0.000 description 1
- JPNKIDWQXJZFDV-UHFFFAOYSA-N 1-(5-bromo-3-chloro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Br)=CC(Cl)=C1O JPNKIDWQXJZFDV-UHFFFAOYSA-N 0.000 description 1
- MGGMXOCLNXDSEQ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C(F)=C1 MGGMXOCLNXDSEQ-UHFFFAOYSA-N 0.000 description 1
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- KUQBICUGNGOJBR-UHFFFAOYSA-N 1-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]phenyl]cyclopropane-1-carbonitrile Chemical group C1C(=O)CC(=O)OC1(C1CCCC1)CCC1=CC=C(C2(CC2)C#N)C=C1 KUQBICUGNGOJBR-UHFFFAOYSA-N 0.000 description 1
- UGNGGNAJJYAKIS-UHFFFAOYSA-N 1-[4-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]phenyl]cyclopropane-1-carbonitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC(C=C1)=CC=C1C1(C#N)CC1 UGNGGNAJJYAKIS-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- PJVJMTXJCINMFE-UHFFFAOYSA-N 2-[4-[2-(2-cyclopentyl-4,6-dioxooxan-2-yl)ethyl]phenyl]-2-methylpropanenitrile Chemical group C1=CC(C(C)(C#N)C)=CC=C1CCC1(C2CCCC2)OC(=O)CC(=O)C1 PJVJMTXJCINMFE-UHFFFAOYSA-N 0.000 description 1
- MGBAEXCSCBZSJW-UHFFFAOYSA-N 2-[4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3h-pyran-2-yl)ethyl]-2,6-difluorophenyl]-2-methylpropanenitrile Chemical compound C1=C(F)C(C(C)(C#N)C)=C(F)C=C1CCC1(C2CCCC2)OC(=O)C=C(O)C1 MGBAEXCSCBZSJW-UHFFFAOYSA-N 0.000 description 1
- NATMCKNXHFGWMH-UHFFFAOYSA-N 2-[4-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]phenyl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC=C(C(C)(C)C#N)C=C1 NATMCKNXHFGWMH-UHFFFAOYSA-N 0.000 description 1
- ZKYWWOXZNCTARW-UHFFFAOYSA-N 2-chloro-1-cyclopentylethanone Chemical compound ClCC(=O)C1CCCC1 ZKYWWOXZNCTARW-UHFFFAOYSA-N 0.000 description 1
- KTRZQCIGJUWSGE-UHFFFAOYSA-N 2-chloropropanedial Chemical compound O=CC(Cl)C=O KTRZQCIGJUWSGE-UHFFFAOYSA-N 0.000 description 1
- DKIQXHIAEMGZGO-UHFFFAOYSA-N 2-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C(C=O)=C1 DKIQXHIAEMGZGO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- ZQQSRVPOAHYHEL-UHFFFAOYSA-N 4-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1F ZQQSRVPOAHYHEL-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- KMWCSNCNHSEXIF-UHFFFAOYSA-N 5-methyl-1h-imidazole-4-carbaldehyde Chemical compound CC=1N=CNC=1C=O KMWCSNCNHSEXIF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- NJCWLDMKORHRSK-UHFFFAOYSA-N B.C#CC(O)(CC1=CC(=O)OC(C)(C)O1)C1CCCC1.CC(C)(C#N)C1=C(F)C=C(Br)C=C1.CC(C)(C#N)C1=CC=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C1F.CC1(C)OC(=O)C=C(CC(O)(C#CC2=CC=C(C(C)(C)C#N)C(F)=C2)C2CCCC2)O1.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)=N\N12.CNC.CO.[H]C(=O)C1=NN2=C(=N1)/N=C(C)\C=C/2C Chemical compound B.C#CC(O)(CC1=CC(=O)OC(C)(C)O1)C1CCCC1.CC(C)(C#N)C1=C(F)C=C(Br)C=C1.CC(C)(C#N)C1=CC=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C1F.CC1(C)OC(=O)C=C(CC(O)(C#CC2=CC=C(C(C)(C)C#N)C(F)=C2)C2CCCC2)O1.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C(C)(C)C#N)C(F)=C4)(C4CCCC4)OC3=O)=N\N12.CNC.CO.[H]C(=O)C1=NN2=C(=N1)/N=C(C)\C=C/2C NJCWLDMKORHRSK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZEMBFWRYYXLRFR-UHFFFAOYSA-N C#CC(CC1=CC(=O)OC(C)(C)O1)(OC(=O)C(=O)OCC)C1CCCC1.C#CC(O)(CC1=CC(=O)OC(C)(C)O1)C1CCCC1 Chemical compound C#CC(CC1=CC(=O)OC(C)(C)O1)(OC(=O)C(=O)OCC)C1CCCC1.C#CC(O)(CC1=CC(=O)OC(C)(C)O1)C1CCCC1 ZEMBFWRYYXLRFR-UHFFFAOYSA-N 0.000 description 1
- GKUUWQKFJSRZAA-UHFFFAOYSA-N C.CC(C)(C#N)C1=CC=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C1F Chemical compound C.CC(C)(C#N)C1=CC=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C1F GKUUWQKFJSRZAA-UHFFFAOYSA-N 0.000 description 1
- XTTRTRBJLNCILX-UHFFFAOYSA-N C.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C5(C#N)CC5)C(F)=C4)(C4CCCC4)OC3=O)=N\N12 Chemical compound C.CC1=CC(C)=N/C2=N/C(CC3=C(O)CC(CCC4=CC=C(C5(C#N)CC5)C(F)=C4)(C4CCCC4)OC3=O)=N\N12 XTTRTRBJLNCILX-UHFFFAOYSA-N 0.000 description 1
- PMWBXLMGBZXREZ-UHFFFAOYSA-N CC1=CC(C)=NC2=NC(CC3CC4=C(O)CC(CCC5=CC=C(C6(C#N)CC6)C=C5)(C5CCCC5)OC4=OC3=O)=NN12 Chemical compound CC1=CC(C)=NC2=NC(CC3CC4=C(O)CC(CCC5=CC=C(C6(C#N)CC6)C=C5)(C5CCCC5)OC4=OC3=O)=NN12 PMWBXLMGBZXREZ-UHFFFAOYSA-N 0.000 description 1
- RNAVLHFTJJRARK-UHFFFAOYSA-N CC1=CC(C)=NC2=NC(CC3CO=C4OC(CCC5=CC=C(C(C)(C)C#N)C=C5)(C5CCCC5)CC(O)=C4C3)=NN12 Chemical compound CC1=CC(C)=NC2=NC(CC3CO=C4OC(CCC5=CC=C(C(C)(C)C#N)C=C5)(C5CCCC5)CC(O)=C4C3)=NN12 RNAVLHFTJJRARK-UHFFFAOYSA-N 0.000 description 1
- ZTSSPNILXXPFPY-UHFFFAOYSA-N CCC1=CN2N=C(CO)N=C2N=C1 Chemical compound CCC1=CN2N=C(CO)N=C2N=C1 ZTSSPNILXXPFPY-UHFFFAOYSA-N 0.000 description 1
- XXXDDNQPUXJFCZ-UHFFFAOYSA-N COC1=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C(F)C(C(C)(C)C#N)=C1 Chemical compound COC1=C(CCC2(C3CCCC3)CC(=O)CC(=O)O2)C=C(F)C(C(C)(C)C#N)=C1 XXXDDNQPUXJFCZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BFQZDMOIGAAQMM-UHFFFAOYSA-N [C-]#[N+]C(C)(C)C1=C(F)C=C(Br)C(OC)=C1 Chemical compound [C-]#[N+]C(C)(C)C1=C(F)C=C(Br)C(OC)=C1 BFQZDMOIGAAQMM-UHFFFAOYSA-N 0.000 description 1
- DLQZTOMUWXWWGW-UHFFFAOYSA-N [C-]#[N+]CC1=C(F)C=C(Br)C(OC)=C1 Chemical compound [C-]#[N+]CC1=C(F)C=C(Br)C(OC)=C1 DLQZTOMUWXWWGW-UHFFFAOYSA-N 0.000 description 1
- NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- DLILIUSWDLJMCE-UHFFFAOYSA-N methyl 4-bromo-2-fluorobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1F DLILIUSWDLJMCE-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity.
- the present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme.
- the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).
- the cytochrome P450 enzyme system comprises over 100 enzymes that modulate various physiological functions.
- the CYP450 enzymes are responsible for metabolizing xenobiotic substances so that they may be eliminated from systemic circulation.
- Most of the CYP450 enzymes responsible for metabolizing such substances in mammals are found in the liver.
- the present invention relates to methods of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (I),
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or2
- t is an integer from 0 to 3.
- R 1 and R 2 may vary as a substituent or be the same.
- m 2
- the phenyl moiety to which R 1 is attached may be substituted with two different R 1 groups or two that are the same.
- cytochrome P450 in another aspect of the present invention are provided methods of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (i), or a pharmaceutically acceptable salt or solvate thereof, wherein the cytochrome P450 is the 2D6 isoform.
- said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor.
- said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- Another aspect of the present invention provides methods of inhibiting cytochrome P450 enzyme activity in a mammal, comprising administering to said mammal a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- cytochrome P450 enzyme activity comprising contacting said cytochrome P450 enzyme with a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
- Still another aspect of the present invention provides methods of decreasing the metabolism in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (I),
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- cytochrome P450 In still another aspect of the present invention are provided methods of decreasing the metabolism in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 —
- m is an integer from 0 to 3;
- n 1 or 2;
- t is an integer from 0 to 3.
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 —
- m is 1, 2 or 3;
- n 1;
- t is 0, 1, or 2;
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- Still another aspect of the present invention provides any of the above-described methods wherein the compound of formula (I) is selected from those of formula (Ib):
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from C 1 -C 4 alkyl, and halogen
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- the present invention also provides any of the above-described methods wherein the compounds of formula (I) are selected from 2-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl ⁇ ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl
- a mammal of a first compound which is metabolized by cytochrome P450 wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor.
- said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of formula (I) are selected from the (R)-enantiomers of 2-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl ⁇ ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[
- any of the methods described herein wherein the compound of formula (I) is substantially enantiomerically pure. Also provided herein are any of the methods described herein wherein the compound of formula (I) is enantiomerically pure.
- compositions comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I),
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from hydrogen, C 1 -C 4 alkyl, and halogen;
- X is —CH 2 or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- compositions comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the at least one cytochrome P450 enzyme is the 2D6 isoform.
- compositions wherein the first compound that is metabolized by at least one cytochrome P450 enzyme is chosen from antagonists of the N-methyl-D-aspartate receptor.
- said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
- compositions comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the first compound is selected from amitryptyline, bisoprolol, captopril, cilostazol, chlorpheniramine, chlorpromazine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, desipramine, dexfenfluramine, dextromethorphan, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, fluoxetine, fluphenazine, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from hydrogen, C 1 -C 4 alkyl, and halogen;
- X is —CH 2 —
- m is an integer from 0 to 3;
- n 1 or 2;
- t is an integer from 0 to 3.
- Another aspect of the present invention provides any of the above-described compositions, wherein in the compound of formula (I):
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from hydrogen, C 1 -C 4 alkyl, and halogen;
- X is —CH 2 —
- m is 1, 2 or 3;
- n 1;
- t is 0, 1, or 2;
- Another aspect of the present invention provides any of the above-described compositions wherein the compound of formula (I) is selected from those of formula (Ia):
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from hydrogen, C 1 -C 4 alkyl, and halogen;
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- each R 1 is independently selected from fluorine, —C(CH 3 ) 2 CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R 2 is independently selected from hydrogen, C 1 -C 4 alkyl, and halogen;
- X is —CH 2 — or —O—
- m is an integer from 0 to 5;
- n 1 or 2;
- t is an integer from 0 to 3.
- compositions wherein the compound of formula (I) is selected from 2-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl ⁇ ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2- ⁇ 2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-
- compositions wherein the compound of formula (I) is chosen from the (R)— or the (S)-enantiomer. Additionally, the present invention provides compositions wherein the compound of formula (I) is substantially enantiomerically pure. Furthermore, the present invention provides compositions wherein the compound of formula (I) is enantiomerically pure.
- compositions of the present invention can comprise any of the embodiments of the compounds of formula (I) described herein.
- cytochrome P450 refers to a family of enzymes found in mammals that modulate various physiological functions. In mammals, these enzymes are found throughout various tissues. About 30 of the enzymes in the cytochrome P450 family are found primarily in the endoplasmic reticulum of hepatocytes in the liver and small intestine, with smaller quantities found in the kidneys, lungs, and brain (E. L. Michalets, Review of Therapeutics, Update: Clinically significant cytochrome P 450 drug interactions, Pharmacotherapy, 1998, 18(1), pp. 84-122; T. F. Woolf, Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999.
- isoform refers to a particular cytochrome P450 enzyme having a particular amino acid sequence.
- cytochrome P450 2D6 refers to the cytochrome P450 enzyme with the amino acid sequence of the CYP 2D6 isoform, also known as debrisoquine hydroxylase, as described for the human population in Gonzalez, et al., Nature 331:442-446 (1988).
- bioavailability refers to the systemic availability of a given amount of a chemical compound administered to a mammal. Bioavailability can be assessed by measuring the area under the curve (AUC) or the maximum serum or plasma concentration (C max ) of the unchanged form of a compound following administration of the compound to a mammal. AUC is a determination of the Area Under the Curve plotting the serum or plasma concentration of a compound along the ordinate (Y-axis) against time along the abscissa (X-axis). Generally, the AUC for a particular compound can be calculated using methods known to those of ordinary skill in the art and as described in G. S. Banker, Modern Pharmaceutics.
- the C max value is defined as the maximum concentration of the compound achieved in the serum or plasma of a mammal following administration of the compound to the mammal.
- the C max value of a particular compound can be measured using methods known to those of ordinary skill in the art.
- the phrase “increasing bioavailability,” as used herein means that the systemic availability of a first compound, measured as AUC or C max , in a mammal is greater when co-administered with a compound of the present invention than when such co-administration does not take place.
- administration refers to the delivery of a compound, or a pharmaceutically acceptable salt or solvate thereof, or of a pharmaceutical composition containing the compound, or a pharmaceutically acceptable salt or solvate thereof, to a mammal such that the compound is absorbed into the serum or plasma of the mammal.
- co-administration refers to the administration of a combination of a first compound and a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof. Such co-administration can be performed such that the first compound and the compound of the present invention are part of the same composition or part of the same unitary dosage form. Co-administration also includes administering a first compound and a compound of the present invention separately, but as part of the same therapeutic regimen. The two components, if administered separately, need not necessarily be administered at essentially the same time, although they can be if so desired. Thus co-administration includes, for example, administering a first compound and a compound of the present invention as separate dosages or dosage forms, but at the same time. Co-administration also includes separate administration at different times and in any order.
- first compound refers to a compound for which it is desired to increase the bioavailability of or decrease the metabolism of using the methods of the present invention.
- cytochrome P450-inhibiting amount and “cytochrome P450 enzyme activity-inhibiting amount,” as used herein, refer to an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, required to decrease the activity of cytochrome P450 enzymes or a particular cytochrome P450 enzyme isoform in the presence of such compound. Whether a particular compound of the present invention decreases cytochrome P450 enzyme activity, and the amount of such a compound required to do so, can be determined by methods known to those of ordinary skill in the art and the methods described herein.
- inhibitors refer to decreasing the activity of a cytochrome P450 enzyme or enzymes using compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Such inhibition may take place by the compound of formula (I) binding directly to the cytochrome P450 enzyme or enzymes. In addition, the activity of such cytochrome P450 enzymes may be decreased in the presence of a compound of formula (I) when such direct binding between the enzyme and the compound of formula (I) does not take place. Furthermore, such inhibition may be competitive, non-competitive, or uncompetitive, as described in T. F. Woolf, Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999. Such inhibition may be determined using in vitro or in vivo systems, or a combination of both, using methods known to those of ordinary skill in the art.
- metabolism or “metabolizing,” as used herein, refer to a process in which a compound is chemically modified by a biological system, such as in vivo in a mammal. Such modifications may also take place in certain in vitro systems known to those of ordinary skill in the art. Metabolism is generally described in T. F. Woolf, Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999.
- C 1 -C 4 alkyl includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties, and containing from 1-4 carbon atoms.
- cyclic moieties including fused and bridged bicyclic and spirocyclic moieties, or a combination of the foregoing moieties, and containing from 1-4 carbon atoms.
- the group must have at least three carbon atoms.
- halogen and “halo,” as used herein represent fluorine, chlorine, bromine or iodine.
- cyano is meant to represent a group —CN.
- substituted means that the specified group or moiety bears one or more substituents.
- unsubstituted means that the specified group bears no substituents.
- optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents.
- phrases “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups, which may be present in the compounds of the present invention.
- solvate is intended to mean a compound of formula (I) in a form such that a molecule of solvent is associated with a molecule of formula (I). It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of formula (I), such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of formula (I), such as a dihydrate. Additionally, it is specifically contemplated that in the present invention less than one solvent molecule may be associated with one molecule of formula (I), such as a hemihydrate. Furthermore, solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
- substantially enantiomerically pure refers to a compound of formula (I) comprising at least about 90% of a single enantiomer (80% enantiomeric excess).
- enantiomerically pure refers to a compound of formula (I) comprising at least about 95% of a single enantiomer (90% enantiomeric excess), or at least about 97.5% of a single enantiomer (95% enantiomeric excess.), or at least about 99% of a single enantiomer (98% enantiomeric excess).
- the compound (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol can also be named as 1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-4-ol.
- the compounds of the present invention may exist in several tautomeric forms.
- a compound of the invention may exist in a form in which two ketones are present on a ring of the compound, as shown in (A) below.
- the compounds of the present invention may exist in at least two different enol forms, as shown in compounds (B) and (C) below. These three forms may be in equilibrium and the compounds of the invention may exist in more than one of these forms at the same time.
- a certain percentage of the molecules may be present in form (A) while the remainder are present in form (B) or form (C).
- the compounds of the present invention may have asymmetric carbon atoms.
- the carbon-carbon bonds in the compounds of the present invention may be depicted herein using a solid line ( ), a solid wedge ( ), or a dotted wedge ( )
- a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers at that carbon atom are included.
- the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom.
- a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
- the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
- Individual enantiomers of the compounds of the present invention can be designated as either the (R)— or (S)-enantiomer using conventional naming protocols known to those of ordinary skill in the art and as described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- the stereochemistry of the individual carbon atoms may be assigned as of either the (R)— or (S)-configuration according to methods known to those of ordinary skill in the art and as described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- Solutions of individual stereoisomeric compounds of the present invention may rotate plane-polarized light.
- the use of either a “(+)” or “( ⁇ )” symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or ( ⁇ ) direction, as measured using techniques known to those of ordinary skill in the art and as described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g., alcohol
- Other methods of separating individual diastereomeric compounds are described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994. All such isomers, including enantiomeric mixtures, diastereomeric mixtures, and pure enantiomers are considered part of the present invention.
- individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis, followed by purification as described above if necessary.
- Asymmetric synthesis may be performed using techniques known to those of ordinary skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods.
- Other methods of preparing enantiomerically pure compounds are described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- the compounds of the present invention contain asymmetric carbon atoms
- the compounds, pharmaceutically acceptable salts or solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
- an optically pure compound is one that is enantiomerically pure.
- the term “optically pure” is intended to mean a compound comprising at least a sufficient activity.
- a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid; and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; and the like.
- an inorganic acid such as hydrochloric acid; hydrobromic acid; sulfuric acid;
- a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
- an inorganic or organic base such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
- Suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
- a “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
- solvates include, but are not limited to, compounds of the invention in combination with water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof.
- a “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified derivative, containing pharmacologically acceptable anions, and is not biologically or otherwise undesirable.
- pharmaceutically acceptable salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate,
- the compounds of the present invention may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
- the compounds of the present invention, and their pharmaceutically acceptable salts and solvates may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
- the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
- the acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained.
- the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
- Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
- the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention.
- Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
- salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
- they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
- stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
- Administration of the compounds, or their pharmaceutically acceptable salts or solvates may be performed according to any suitable mode of administration available to one of ordinary skill in the art.
- suitable modes of administration include oral, nasal, parenteral, topical, transdermal, rectal, or by inhalation or spray.
- such delivery may be performed by orally administering a first compound, or a pharmaceutically acceptable salt thereof, and a compound of the invention, or a pharmaceutically acceptable salt thereof, to a mammal, such as a human.
- the first compound and a compound of the present invention, and any additional compounds may be administered in the form of a pharmaceutically acceptable formulation containing non-toxic, pharmaceutically acceptable carriers, adjuvants and vehicles.
- the first compound and a compound of formula (I), or pharmaceutically acceptable salts or solvates thereof may be administered to a mammal by other routes of administration including, but not limited to, intravenous, topical, sublingual, parenteral, rectal, or by inhalation or spray.
- Such alternative administration may be performed with the first compound and a compound of the present invention alone or in dosage unit formulations containing non-toxic, pharmaceutically acceptable carriers, adjuvants and vehicles.
- the present invention specifically contemplates that the first compound and the compound of the present invention may be co-administered using different forms of administration for each.
- the first compound may be administered topically while the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, may be administered orally.
- the preferred formulation and route of administration of the first compound and the compound of the present invention to a mammal will depend on the age and condition of the mammal, the condition being treated, the identity of the first compound, the identity of the compound of the present invention, and other factors known to those of ordinary skill in the art.
- the formulation and route of administration can be determined by one of ordinary skill in the art without undue experimentation.
- compositions are known or may be routinely determined by those skilled in the art.
- pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
- compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use.
- Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions.
- Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid.
- Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water.
- the carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- a suitable prolonged-release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
- the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
- a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
- the amount and timing of compounds administered will, of course, be based on the judgement of the prescribing physician.
- the dosages provided are a guideline and one of ordinary skill in the art may titrate doses of the agent to achieve the activity that they consider appropriate for the individual subject.
- one of skill in the art must balance a variety of factors such as cognitive function, age of the patient, presence of preexisting disease, as well as presence of other diseases (e.g., cardiovascular).
- compositions of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle or diluent.
- the compounds of this invention can be administered individually or together with the first compound(s) in any conventional dosage form.
- a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like.
- Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
- binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
- compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
- preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
- lactose or milk sugar as well as high molecular weight polyethylene glycols.
- the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
- solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts.
- aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
- the sterile aqueous media employed are all readily obtainable by standard techniques known to those skilled in the art.
- aqueous or partially aqueous solutions are prepared.
- the compounds of the present invention can be prepared by procedures known to those of ordinary skill in the art and as described in co-pending U.S. patent application Ser. No.10/718,337, which is hereby incorporated by reference.
- Et 2 O diethyl ether
- DMF N,N-dimethylformamide
- DMSO dimethylsulfoxide
- MeOH methanol
- EtOH ethanol
- EtOAc ethyl acetate
- Ac acetyl
- Hex hexane
- Me Me
- Ph phenyl
- DIEA diisopropylethylamine
- TFA trifluoroacetic acid
- DTT dithiothreitol
- THF tetrahydrofuran
- Solid-phase syntheses were performed by immobilizing reagents with Rink amide linkers (Rink, Tetrahedron Letters (1987) 28:3787), which are standard acid-cleavable linkers that upon cleavage generate a free carboxamide group.
- Rink amide linkers Rink, Tetrahedron Letters (1987) 28:3787
- Small-scale solid-phase syntheses e.g., about 2-5 ⁇ mole, were performed using Chiron SynPhasee polystyrene O-series crowns (pins) derivatized with Fmoc-protected Rink amide linkers.
- the Rink amide linkages were formed to Argonaut Technologies Argogel® resin, a grafted polystyrene-poly(ethylene glycol) copolymer.
- Any suitable resin may be used as the solid phase, selected from resins that are physically resilient and that, other than with regard to the linking and cleavage reactions, are inert to the synthetic reaction conditions.
- the reaction was quenched with 10 mL saturated NH 4 Cl and 5 mL water. To this was added 20 mL CH 2 Cl 2 and the pH of the aqueous phase was adjusted to 3. The layers were separated, and the aqueous layer was extracted with 3 ⁇ 30 mL 10% MeOH in CH 2 Cl 2 . The organic layers were combined, and dried over Na 2 SO 4 . After filtering off the solids, the liquid was concentrated by rotary evaporation to an oil. The oil was flash chromatographed, and the resulting product was further purified by preparatory HPLC.
- Step 3 2- ⁇ 4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile
- Step 4 2- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl)-2-methyl-propionitrile
- Step 3 Acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-ethyl-phenyl ester.
- Step 4 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
- Step 2 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile
- Step 3 1- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile
- the desired compound can also be separated from racemic 2-(4- ⁇ 2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl ⁇ -2-fluoro-phenyl)-2-methyl-propionitrile. (100 mg) using chiral HPLC (Chiralpak AS—RH, 150 ⁇ 4.6 mm, 0.6 mL/min, 50% CAN, 50% H 2 O, 30° C.). (40 mg, 80% recovery, 14.743 min retention time).
- Step 1 Preparation of compound (+)-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one
- Step 2 (+)-2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile
- Step 2 Preparation of Compound 5-Bromo-1-chloro-3-ethyl-2-(2-methoxy-ethoxymethoxy)-benzene.
- Step 3 3-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-1-cyclopentyl-propan-1-one
- Step 4 6- ⁇ 2-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran-2,4-dione
- Step 5 6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione
- Trifluoroacetic acid (0.07 mL, 0.88 mmol) was added to a solution of 6- ⁇ 2-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran-2,4-dione (0.2 g, 0.44 mmol) dissolved in CH 2 Cl 2 (4 mL).
- the reaction mixture was stirred for 2 hours at room temperature and then partitioned between H 2 O and EtOAc. The organic extracts were washed with brine, dried over Na 2 SO 4 and concentrated to an oil.
- Step 4 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6-difluoro-phenyl ⁇ -2-methyl-propionitrile
- Step 5 2- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl ⁇ -2-methyl-propionitrile
- the oil was purified by flash chromatography (50 g SiO 2 , 70% ethyl acetate, 6% methanol, 0.5% acetic acid, 23.5% hexanes) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder (142 mg, 18%).
- the oil was purified by flash chromatography (50 g SiO 2 , 70% ethyl acetate, 6% methanol, 0.5% acetic acid, 23.5% hexanes).
- the resultant oil was further purified by flash 50 g SiO 2 , 1:3 ⁇ 1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid) to give the desired product as an oil.
- Step 4 Preparation of Compound 2-[4-(2-Cyclopentyl-2-oxo-ethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile
- Step 5 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile
- Step 1 2- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile
- the desired product was prepared analogously to example 1, substituting 6-cyclopentyl-6- ⁇ 2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl ⁇ dihydro-2H-pyran-2,4(3H)-dione from Step 3 below, in place of 2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile and 6-chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, from example 12 (step 2) in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde.
- Step 2 Preparation of compound 1-cyclopentyl-3-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]propan-1-one
- Step 3 6-cyclopentyl-6- ⁇ 2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl ⁇ dihydro-2H-pyran-2,4(3H)-dione
- the precipitate was removed by filtration, and the filtrate was concentrated to a crude oil.
- the crude oil was purified by flash chromatography (25 g SiO 2 , 1:3:1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid):(81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give product as an oil. It was further purified by preparatory HPLC. Yield: 19.0 mg, 8.0%.
- the organic liquid was concentrated to a thick oil, and then purified by flash chromatography (50 g SiO 2 , 3:10 ⁇ 3:5 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder.
- the aqueous layer was extracted with 2 ⁇ 50 mL of CH 2 Cl 2 , and the organic layers were combined. After drying the liquid over MgSO 4 , the solids were filtered away, and the organic was concentrated to an oil. It was further purified by flash chromatography (90 g SiO 2 , 1:99 ⁇ 1:20 (EtOAc/Hexanes) to give the desired product (2.81 g, 59%).
- Step 2 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ -cyclobutanecarbonitrile
- Step 3 1- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -cyclobutanecarbonitrile
- Step 3 1- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl ⁇ -cyclopropanecarbonitrile
- Step 6 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-5-methoxy-phenyl ⁇ -2-methyl-propionitrile
- Step 7 2- ⁇ 4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]-2-fluoro-5-methoxy-phenyl ⁇ -2-methyl-propionitrile
- the desired product is prepared analogously to example 1, substituting 2- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl ⁇ -2-methyl-propionitrile in place of 2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile of that example.
- the desired product is prepared analogously to example 1, substituting 1- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl ⁇ -cyclopropanecarbonitrile in place of 2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile of that example.
- the desired compound can also be separated from racemic 2-(4- ⁇ 2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl ⁇ -2-fluoro-phenyl)-2-methyl-propionitrile. (100 mg) using chiral HPLC (Chiralpak AS-RH, 150 ⁇ 4.6 mm, 0.6 mL/min, 50% CAN, 50% H 2 O, 30° C.). (38 mg, 76% recovery, 7.536 min retention time).
- Step 1 Preparation of compound 1-cyclopentyl-1-[(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methyl]prop-2-ynyl ethyl oxalate
- Step 2 Preparation of compound ( ⁇ )-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one
- Step 3 Preparation of compound ( ⁇ )-2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile.
- Method for determining inhibition of cytochrome P450 2D6 Compounds of interest at 0.3 ⁇ M, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M, and 30 ⁇ M concentrations, 8 ⁇ M dextromethorphan and 1 mM NADPH were incubated with human liver microsomes (0.25 mg/mL protein and 0.075 ⁇ M P450) at 37° C. for 20 min. Following the 20 min incubation, the reaction was quenched by addition of 200 ⁇ L acetonitrile containing 0.1 ⁇ M buspirone as an internal standard. The samples were then vortex mixed and centrifuged to pellet the protein. The supernantant was transferred, dried under nitrogen flow and reconstituted in mobile phase.
- % R % R max ⁇ (1 ⁇ (C/(C+IC 50 ))) using WinNonLin (version 4.0.1), where % R is the % remaining CYP 2D6 activity relative to the vehicle control, C is the concentration of the compound of interest, and IC 50 is the inhibitory concentration of the compound of interest giving 50% inhibition of maximal % remaining activity.
- IC 50 is the inhibitory concentration of the compound of interest giving 50% inhibition of maximal % remaining activity.
- IC 50 is reported as IC 50 s ( ⁇ M). If more than one assay was performed for a particular compound, the average IC 50 is reported with the number of tests in parentheses.
Abstract
The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).
Description
- This application claims priority to U.S. Patent Application Nos. 60/449088, filed Feb. 21, 2003, 60/472355, filed May 20, 2003, and U.S. Ser. No. 10/718337, filed Nov. 19, 2003.
- The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).
- In mammals, the cytochrome P450 enzyme system comprises over 100 enzymes that modulate various physiological functions. In particular, the CYP450 enzymes are responsible for metabolizing xenobiotic substances so that they may be eliminated from systemic circulation. Most of the CYP450 enzymes responsible for metabolizing such substances in mammals are found in the liver.
- It is known that some drugs, when administered to mammals, are metabolized by cytochrome P450 monooxygenase enzymes. The drug metabolites that result may, in some cases, be inactive in mammals and therefore may not produce a desired physiological effect. With some drugs, this metabolism by CYP450 enzymes to produce inactive metabolites may be so extensive that the pharmacokinetics of the drug are unfavorable, thereby requiring more frequent and higher doses of the drug than are desirable to achieve a desired physiological effect. Therefore, administration of such drugs in combination with an agent or agents that inhibit the CYP450 enzymes can improve the pharmacokinetics of such drugs by decreasing their metabolism by CYP450 enzymes. In turn, improved pharmacokinetics of a drug may have the advantages of decreasing both the dose and dosing frequency of the drug required to observe a desired physiological effect. Thus, the need exists for compounds that will inhibit CYP450 enzymes.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- It is to be understood that when t or m is an integer greater than 1, R1 and R2 may vary as a substituent or be the same. For example, where m is 2, the phenyl moiety to which R1 is attached may be substituted with two different R1 groups or two that are the same.
- It is also to be understood that in the compounds of formula (I), when m is less than 5 and t is less than 3, the remaining positions on the phenyl and [1,2,4]triazolo[1,5a]pyrimidinyl rings, respectively, are substituted with hydrogen. For example, when m is 1, the remaining 4 positions on the phenyl ring contain hydrogen substituents. Similarly, when t is 1, for example, the remaining two positions on the [1,2,4]triazolo[1,5a]pyrimidinyl ring contain hydrogen substituents.
- In another aspect of the present invention are provided methods of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (i), or a pharmaceutically acceptable salt or solvate thereof, wherein the cytochrome P450 is the 2D6 isoform.
- Also provided in the present invention are methods of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, wherein the first compound is selected from alprenolol, amiflamine, amitryptyline, aprindine, atomoxetine, bisoprolol, brofaromine, bufuralol, bunitrolol, bupronolol, captopril, chlorpheniramine, chlorpromazine, cilostazol, cinnarizine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, debrisoquine, desipramine, desmethylcitalopram, dexfenfluramine, dextromethorphan, dihydrocodine, dolasetron, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, flunarizine, fluvoxamine, fluoxetine, fluphenazine, guanoxan, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine, methamphetamine, methoxyamphetamine, 5-methoxyindoleethylamine, methoxyphenamine, methylenedioxymethamphetamine, metoprolol, mexiletine, mianserin, minaprine, morphine, nefazodone, nelfinavir, norcodeine, nortryptyline, ondansetron, omeprazole, oxycodone, paclitaxel, paroxetine, perhexiline, perphenazine, phenformin, procodeine, promethazine, N-propylajmaline, propafenone, propanolol, retinoic acid, quinidine, risperidone, ritonavir, RU-486, sparteine, tamoxifen, testosterone, thioridazine, timolol, tolterodine, tomoxatene, tramadol, trazodone, trifluperidol, trimipramine, tropisetron, venlafaxine, vinblastine, and zuclopenthixol.
- In still another aspect of the present invention are provided methods as above, wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor. In yet another aspect of the present invention are provided such methods wherein said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- Another aspect of the present invention provides methods of inhibiting cytochrome P450 enzyme activity in a mammal, comprising administering to said mammal a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- In yet another aspect of the present invention are provided methods of inhibiting cytochrome P450 enzyme activity, comprising contacting said cytochrome P450 enzyme with a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- In still another aspect of the present invention are provided methods of decreasing the metabolism in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (I), wherein the cytochrome P450 enzyme is the 2D6 isoform.
- In another aspect of the present invention are provided any of above-described methods wherein in the compound of formula (I):
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2—;
- m is an integer from 0 to 3;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- In yet another aspect of the present invention are provided any of the above-described methods wherein in the compound of formula (I):
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2—;
- m is 1, 2 or 3;
- n is 1;
- t is 0, 1, or 2; and
- pharmaceutically acceptable salts and solvates thereof.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- The present invention also provides any of the above-described methods wherein the compounds of formula (I) are selected from 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl)-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-(2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
- In another aspect of the present invention are provided methods of decreasing the metabolism in a mammal of a first compound which is metabolized by cytochrome P450, wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor. Also provided in the present invention are such methods wherein said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
- Also provided in the present invention are any of the above-described methods wherein the compounds of formula (I) are selected from the (R)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-(2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
- In yet another aspect of the present invention are provided any of the above-described methods wherein the compounds of formula (I) are selected from the (S)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
- In yet another aspect of the present invention are provided any of the methods described herein wherein the compound of formula (I) is substantially enantiomerically pure. Also provided herein are any of the methods described herein wherein the compound of formula (I) is enantiomerically pure.
- It is understood that the present invention contemplates the use of any of the described embodiments of the compounds of formula (I) in any of the methods described herein.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
- X is —CH2 or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- Also provided herein are compositions comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the at least one cytochrome P450 enzyme is the 2D6 isoform.
- In another aspect of the present invention are provided such compositions, wherein the first compound that is metabolized by at least one cytochrome P450 enzyme is chosen from antagonists of the N-methyl-D-aspartate receptor. In a further aspect of the present invention are provided such methods wherein said antagonist of the N-methyl-D-aspartate receptor is (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
- In yet another aspect of the present invention are provided compositions comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I), wherein the first compound is selected from amitryptyline, bisoprolol, captopril, cilostazol, chlorpheniramine, chlorpromazine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, desipramine, dexfenfluramine, dextromethorphan, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, fluoxetine, fluphenazine, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine, methamphetamine, metoprolol, mexiletine, morphine, nefazodone, nelfinavir, nortryptyline, ondansetron, omeprazole, oxycodone, paclitaxel, paroxetine, perphenazine, phenformin, propafenone, propanolol, retinoic acid, quinidine, risperidone, ritonavir, RU-486, tamoxifen, testosterone, timolol, tramadol, trazodone, trifluperidol, trimipramine, venlafaxine, and vinblastine.
- In still another aspect of the present invention are provided any of the above-described compositions, wherein in the compound of formula (I):
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
- X is —CH2—;
- m is an integer from 0 to 3;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- Another aspect of the present invention provides any of the above-described compositions, wherein in the compound of formula (I):
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
- X is —CH2—;
- m is 1, 2 or 3;
- n is 1;
- t is 0, 1, or 2; and
- pharmaceutically acceptable salts and solvates thereof.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
-
- wherein:
- each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
- each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
- X is —CH2— or —O—;
- m is an integer from 0 to 5;
- n is 1 or 2;
- t is an integer from 0 to 3; and
- pharmaceutically acceptable salts and solvates thereof.
- Also provided herein are any of the above-described compositions, wherein the compound of formula (I) is selected from 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof. Also provided herein are any of the above-described compositions wherein the compound of formula (I) is chosen from the (R)— or the (S)-enantiomer. Additionally, the present invention provides compositions wherein the compound of formula (I) is substantially enantiomerically pure. Furthermore, the present invention provides compositions wherein the compound of formula (I) is enantiomerically pure.
- It is to be understood that any of the compositions of the present invention can comprise any of the embodiments of the compounds of formula (I) described herein.
- The term “cytochrome P450,” as used herein, refers to a family of enzymes found in mammals that modulate various physiological functions. In mammals, these enzymes are found throughout various tissues. About 30 of the enzymes in the cytochrome P450 family are found primarily in the endoplasmic reticulum of hepatocytes in the liver and small intestine, with smaller quantities found in the kidneys, lungs, and brain (E. L. Michalets,Review of Therapeutics, Update: Clinically significant cytochrome P450 drug interactions, Pharmacotherapy, 1998, 18(1), pp. 84-122; T. F. Woolf, Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999. The term “isoform,” as used herein, refers to a particular cytochrome P450 enzyme having a particular amino acid sequence. The terms, “cytochrome P450 2D6,” “CYP 2D6,” or “2D6,” as used herein, refer to the cytochrome P450 enzyme with the amino acid sequence of the CYP 2D6 isoform, also known as debrisoquine hydroxylase, as described for the human population in Gonzalez, et al., Nature 331:442-446 (1988).
- As used herein, the term “bioavailability” refers to the systemic availability of a given amount of a chemical compound administered to a mammal. Bioavailability can be assessed by measuring the area under the curve (AUC) or the maximum serum or plasma concentration (Cmax) of the unchanged form of a compound following administration of the compound to a mammal. AUC is a determination of the Area Under the Curve plotting the serum or plasma concentration of a compound along the ordinate (Y-axis) against time along the abscissa (X-axis). Generally, the AUC for a particular compound can be calculated using methods known to those of ordinary skill in the art and as described in G. S. Banker, Modern Pharmaceutics. Drugs and the Pharmaceutical Sciences, V. 72, Marcel Dekker, New York, Inc., 1996. The Cmax value is defined as the maximum concentration of the compound achieved in the serum or plasma of a mammal following administration of the compound to the mammal. The Cmax value of a particular compound can be measured using methods known to those of ordinary skill in the art. The phrase “increasing bioavailability,” as used herein means that the systemic availability of a first compound, measured as AUC or Cmax, in a mammal is greater when co-administered with a compound of the present invention than when such co-administration does not take place.
- The terms “administration”, “administering”, “dosage,” and “dosing,” as used herein refer to the delivery of a compound, or a pharmaceutically acceptable salt or solvate thereof, or of a pharmaceutical composition containing the compound, or a pharmaceutically acceptable salt or solvate thereof, to a mammal such that the compound is absorbed into the serum or plasma of the mammal.
- The terms “co-administration” or “co-administering,” as used herein, refer to the administration of a combination of a first compound and a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof. Such co-administration can be performed such that the first compound and the compound of the present invention are part of the same composition or part of the same unitary dosage form. Co-administration also includes administering a first compound and a compound of the present invention separately, but as part of the same therapeutic regimen. The two components, if administered separately, need not necessarily be administered at essentially the same time, although they can be if so desired. Thus co-administration includes, for example, administering a first compound and a compound of the present invention as separate dosages or dosage forms, but at the same time. Co-administration also includes separate administration at different times and in any order.
- The term “first compound,” as used herein, refers to a compound for which it is desired to increase the bioavailability of or decrease the metabolism of using the methods of the present invention.
- The terms “cytochrome P450-inhibiting amount” and “cytochrome P450 enzyme activity-inhibiting amount,” as used herein, refer to an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, required to decrease the activity of cytochrome P450 enzymes or a particular cytochrome P450 enzyme isoform in the presence of such compound. Whether a particular compound of the present invention decreases cytochrome P450 enzyme activity, and the amount of such a compound required to do so, can be determined by methods known to those of ordinary skill in the art and the methods described herein.
- The terms “inhibiting” or “inhibition,” as used herein, refer to decreasing the activity of a cytochrome P450 enzyme or enzymes using compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Such inhibition may take place by the compound of formula (I) binding directly to the cytochrome P450 enzyme or enzymes. In addition, the activity of such cytochrome P450 enzymes may be decreased in the presence of a compound of formula (I) when such direct binding between the enzyme and the compound of formula (I) does not take place. Furthermore, such inhibition may be competitive, non-competitive, or uncompetitive, as described in T. F. Woolf,Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999. Such inhibition may be determined using in vitro or in vivo systems, or a combination of both, using methods known to those of ordinary skill in the art.
- The terms “metabolism” or “metabolizing,” as used herein, refer to a process in which a compound is chemically modified by a biological system, such as in vivo in a mammal. Such modifications may also take place in certain in vitro systems known to those of ordinary skill in the art. Metabolism is generally described in T. F. Woolf,Handbook of Drug Metabolism, Marcel Dekker, Inc., New York, 1999.
- The term “C1-C4 alkyl”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties, and containing from 1-4 carbon atoms. For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.
- The terms “halogen” and “halo,” as used herein represent fluorine, chlorine, bromine or iodine.
- The term “cyano,” as used herein, is meant to represent a group —CN.
- The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents.
- The phrase “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic or basic groups, which may be present in the compounds of the present invention.
- The term “solvate,” as used herein, is intended to mean a compound of formula (I) in a form such that a molecule of solvent is associated with a molecule of formula (I). It is specifically contemplated that in the present invention one solvent molecule can be associated with one molecule of formula (I), such as a hydrate. Furthermore, it is specifically contemplated that in the present invention, more than one solvent molecule may be associated with one molecule of formula (I), such as a dihydrate. Additionally, it is specifically contemplated that in the present invention less than one solvent molecule may be associated with one molecule of formula (I), such as a hemihydrate. Furthermore, solvates of the present invention are contemplated as solvates of compounds of the present invention that retain the biological effectiveness of the non-hydrate form of the compounds.
- The term “substantially enantiomerically pure,” as used herein, refers to a compound of formula (I) comprising at least about 90% of a single enantiomer (80% enantiomeric excess). The term “enantiomerically pure,” as used herein refers to a compound of formula (I) comprising at least about 95% of a single enantiomer (90% enantiomeric excess), or at least about 97.5% of a single enantiomer (95% enantiomeric excess.), or at least about 99% of a single enantiomer (98% enantiomeric excess).
- The compound (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol can also be named as 1-[(1S,2S)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-phenylpiperidin-4-ol.
- The compounds of the present invention may exist in several tautomeric forms. For example, a compound of the invention may exist in a form in which two ketones are present on a ring of the compound, as shown in (A) below. Alternatively, the compounds of the present invention may exist in at least two different enol forms, as shown in compounds (B) and (C) below. These three forms may be in equilibrium and the compounds of the invention may exist in more than one of these forms at the same time. For example, in a particular compound of the invention, a certain percentage of the molecules may be present in form (A) while the remainder are present in form (B) or form (C). Which form predominates in a particular compound of the invention depends on several factors that include, but are not limited to, whether the compound is in solid, liquid, or crystalline form, whether the compound is dissolved in a solvent and the identity of the solvent, the environmental temperature, and the relative humidity. It is specifically contemplated that when the compounds of the present invention are drawn in a particular form, form (A) for example, all the tautomeric forms, forms (B) and (C) for example, are included as well.
- The compounds of the present invention may have asymmetric carbon atoms. The carbon-carbon bonds in the compounds of the present invention may be depicted herein using a solid line (), a solid wedge (), or a dotted wedge () The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
- Individual enantiomers of the compounds of the present invention can be designated as either the (R)— or (S)-enantiomer using conventional naming protocols known to those of ordinary skill in the art and as described in E. L. Eliel, et al.,Stereochemistry of Organic Compounds, Wiley: New York, 1994. Furthermore, when a compound of the present invention contains more than one chiral carbon atom, the stereochemistry of the individual carbon atoms may be assigned as of either the (R)— or (S)-configuration according to methods known to those of ordinary skill in the art and as described in E. L. Eliel, et al., Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- Solutions of individual stereoisomeric compounds of the present invention may rotate plane-polarized light. The use of either a “(+)” or “(−)” symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or (−) direction, as measured using techniques known to those of ordinary skill in the art and as described in E. L. Eliel, et al.,Stereochemistry of Organic Compounds, Wiley: New York, 1994.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Other methods of separating individual diastereomeric compounds are described in E. L. Eliel, et al.,Stereochemistry of Organic Compounds, Wiley: New York, 1994. All such isomers, including enantiomeric mixtures, diastereomeric mixtures, and pure enantiomers are considered part of the present invention.
- Alternatively, individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis, followed by purification as described above if necessary. Asymmetric synthesis may be performed using techniques known to those of ordinary skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods. Other methods of preparing enantiomerically pure compounds are described in E. L. Eliel, et al.,Stereochemistry of Organic Compounds, Wiley: New York, 1994. The choice of which method is used will depend on factors that include, but are not limited to, the availability of starting materials, the relative efficiency of a method, and whether such methods are useful for the compounds of the invention containing particular functional groups. Such choices are within the knowledge of one of ordinary skill in the art.
- When the compounds of the present invention contain asymmetric carbon atoms, the compounds, pharmaceutically acceptable salts or solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
- As generally understood by those skilled in the art, an optically pure compound is one that is enantiomerically pure. As used herein, the term “optically pure” is intended to mean a compound comprising at least a sufficient activity.
- If a derivative used in the method of the invention is a base, a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid; and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; and the like.
- If a derivative used in the method of the invention is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative Examples of suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
- A “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates include, but are not limited to, compounds of the invention in combination with water, isopropanol, ethanol, methanol, dimethylsulfoxide (DMSO), ethyl acetate, acetic acid, ethanolamine, or mixtures thereof.
- A “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified derivative, containing pharmacologically acceptable anions, and is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and methoxybenzoate), bicarbonate, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hexyne-1,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methane-sulfonate, methylsulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, pyrophosphate, pyrosulfate, salicylate, stearate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosylate, triethiodode, and valerate salts.
- It is understood by those of ordinary skill in the art that the compounds of the present invention, or their pharmaceutically acceptable salts or solvates, may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas. In addition, the compounds of the present invention, and their pharmaceutically acceptable salts and solvates, may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
- The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially equivalent amount of the selected mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate mineral or organic acid to the solution.
- Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
- Administration of the compounds, or their pharmaceutically acceptable salts or solvates, may be performed according to any suitable mode of administration available to one of ordinary skill in the art. Examples of such suitable modes of administration include oral, nasal, parenteral, topical, transdermal, rectal, or by inhalation or spray.
- For example, such delivery may be performed by orally administering a first compound, or a pharmaceutically acceptable salt thereof, and a compound of the invention, or a pharmaceutically acceptable salt thereof, to a mammal, such as a human. Furthermore, the first compound and a compound of the present invention, and any additional compounds, may be administered in the form of a pharmaceutically acceptable formulation containing non-toxic, pharmaceutically acceptable carriers, adjuvants and vehicles. Alternatively, the first compound and a compound of formula (I), or pharmaceutically acceptable salts or solvates thereof, may be administered to a mammal by other routes of administration including, but not limited to, intravenous, topical, sublingual, parenteral, rectal, or by inhalation or spray. Such alternative administration may be performed with the first compound and a compound of the present invention alone or in dosage unit formulations containing non-toxic, pharmaceutically acceptable carriers, adjuvants and vehicles. In addition, the present invention specifically contemplates that the first compound and the compound of the present invention may be co-administered using different forms of administration for each. For example, the first compound may be administered topically while the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, may be administered orally. The preferred formulation and route of administration of the first compound and the compound of the present invention to a mammal will depend on the age and condition of the mammal, the condition being treated, the identity of the first compound, the identity of the compound of the present invention, and other factors known to those of ordinary skill in the art. The formulation and route of administration can be determined by one of ordinary skill in the art without undue experimentation.
- Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions are known or may be routinely determined by those skilled in the art. For example, pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
- Pharmaceutical compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use. Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions. Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
- Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, seeRemington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition, 1975.
- It will be appreciated that the actual dosages of the compounds of the present invention, or pharmaceutically acceptable salts thereof, used in the pharmaceutical compositions of this invention will be selected according to the properties of the particular agent being used, the particular composition formulated, the mode of administration, the particular site, the host, and the condition being treated. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage-determination tests. For oral administration, e.g., a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
- The amount and timing of compounds administered will, of course, be based on the judgement of the prescribing physician. Thus, because of subject-to-subject variability, the dosages provided are a guideline and one of ordinary skill in the art may titrate doses of the agent to achieve the activity that they consider appropriate for the individual subject. In considering the degree of activity desired, one of skill in the art must balance a variety of factors such as cognitive function, age of the patient, presence of preexisting disease, as well as presence of other diseases (e.g., cardiovascular).
- The compositions of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle or diluent. Thus, the compounds of this invention can be administered individually or together with the first compound(s) in any conventional dosage form.
- For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
- For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques known to those skilled in the art.
- For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.
- Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples, seeRemington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition, 1975.
- The compounds of the present invention can be prepared by procedures known to those of ordinary skill in the art and as described in co-pending U.S. patent application Ser. No.10/718,337, which is hereby incorporated by reference.
- Specific Examples of various compounds according to the invention may be advantageously prepared as set out in the Examples above.
- The structures of the compounds of the following Examples were confirmed by one or more of the following: proton magnetic resonance spectroscopy, infrared spectroscopy, elemental microanalysis, mass spectrometry, thin layer chromatography, melting point, boiling point, and HPLC.
- Proton magnetic resonance (1H NMR) spectra were determined using a 300 megahertz Tech-Mag, Bruker Avance 300DPX, or Bruker Avance 500 DRX spectrometer operating at a field strength of 300 or 500 megahertz (MHz). Chemical shifts are reported in parts per million (ppm, ?) downfield from an internal tetramethylsilane standard. Alternatively, 1H NMR spectra were referenced to residual protic solvent signals as follows: CHCl3=7.26 ppm; DMSO=2.49 ppm; C6HD5=7.15 ppm. Peak multiplicities are designated as follows: s=singlet; d=doublet; dd=doublet of doublets; t=triplet; q=quartet; br=broad resonance; and m=multiplet. Coupling constants are given in Hertz. Infrared absorption (IR) spectra were obtained using a Perkin-Elmer 1600 series FTIR spectrometer. Elemental microanalyses were performed by Atlantic Microlab Inc. (Norcross, Ga.) and gave results for the elements stated within 10.4% of the theoretical values. Flash column chromatography was performed using Silica gel 60 (Merck Art 9385). Analytical thin layer chromatography (TLC) was performed using precoated sheets of Silica 60 F254 (Merck Art 5719). HPLC chromatographs were run on a Hewlett Packard Model 1100 system fitted with a Zorbax SB-C18 4.6 mm×150 mm column having 3.5 micron packing material. Unless otherwise stated, a ramp of 5% CH3CN/H2O to 95% CH3CN/H2O over 7.5 minutes then holding at 95% CH3CN/H2O for 2.5 minutes (both solvents contained 0.1% v/v TFA) at a flow of 1 mL/min was used. Retention times (Rt) are given in minutes. Semi-preparative HPLC samples were run on a Gilson LC3D system fitted with a 21.2 mm×250 mm C8 column. Ramps were optimized for each compound with a CH3CN/H2O solvent system. Melting points were determined on a Mel-Temp apparatus and are uncorrected. All reactions were performed in septum-sealed flasks under a slight positive pressure of argon, unless otherwise noted. All commercial reagents were used as received from their respective suppliers with the following exceptions: tetrahydrofuran (THF) was distilled from sodium-benzophenone ketyl prior to use; dichloromethane (CH2Cl2) was distilled from calcium hydride prior to use; anhydrous lithium chloride was prepared by heating at 110° C. under vacuum overnight. Mass spectra, both low and high resolution, were measured using either electrospray (El) or fast atom bombardment (FAB) ionization techniques.
- The following abbreviations are used herein: Et2O (diethyl ether); DMF (N,N-dimethylformamide); DMSO (dimethylsulfoxide); MeOH (methanol); EtOH (ethanol); EtOAc (ethyl acetate); Ac (acetyl); Hex (hexane); Me (methyl); Et (ethyl); Ph (phenyl); DIEA (diisopropylethylamine); TFA (trifluoroacetic acid); DTT (dithiothreitol); and THF (tetrahydrofuran); and (precipitate); min. or min (minutes); h (hours).
- Solid-phase syntheses were performed by immobilizing reagents with Rink amide linkers (Rink,Tetrahedron Letters (1987) 28:3787), which are standard acid-cleavable linkers that upon cleavage generate a free carboxamide group. Small-scale solid-phase syntheses, e.g., about 2-5 μmole, were performed using Chiron SynPhasee polystyrene O-series crowns (pins) derivatized with Fmoc-protected Rink amide linkers. For larger scale (e.g., greater than about 100 μmole) syntheses, the Rink amide linkages were formed to Argonaut Technologies Argogel® resin, a grafted polystyrene-poly(ethylene glycol) copolymer. Any suitable resin may be used as the solid phase, selected from resins that are physically resilient and that, other than with regard to the linking and cleavage reactions, are inert to the synthetic reaction conditions.
-
-
-
- To a solution of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile (0.40 g, 1.1 mmol) from Step 4 below, in MeOH (7 mL) was added 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.19 g, 1.08 mmol), described in Step 7 below and borane-dimethylamine complex (76 mg, 1.3 mmol) and stirred at room temperature for 3 hours. The reaction was quenched with 10 mL saturated NH4Cl and 5 mL water. To this was added 20 mL CH2Cl2 and the pH of the aqueous phase was adjusted to 3. The layers were separated, and the aqueous layer was extracted with 3×30 mL 10% MeOH in CH2Cl2. The organic layers were combined, and dried over Na2SO4. After filtering off the solids, the liquid was concentrated by rotary evaporation to an oil. The oil was flash chromatographed, and the resulting product was further purified by preparatory HPLC.
- Yield: 28 mg, 5%.1H NMR (400 MHz, DMSO-d6): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78(d, J=16 Hz, 1H), 3.71(d, J=16 Hz, 1H), 3.84 (d, J=16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1H), 10.88 (s, 1H) MS (ESI): 530 (M−H).
-
- To a solution of 4-bromo-1-bromomethyl-2-fluoro-benzene (8.15 g, 30.4 mmol) dissolved in DMF (16 mL) were added sodium cyanide (2.24 g, 45.6 mmol) and water (2 mL). The reaction was stirred for one hour at 70° C. To the reaction was added 130 mL water; 120 mL saturated NaHCO3, and 100 mL EtOAc. The layers were separated, and the aqueous layer was extracted with 3×100 mL EtOAc. The combined organics were washed with 100 mL water, and then dried over Na2SO4. After filtering off the solids, the mother liquor was concentrated to the desired product by rotary evaporation (6.5 g, 99% yield). MS (APCI): 240 (M+H), 242 (M+2+H).
-
- To a slurry of sodium hydride (60% dispersion in mineral oil, 0.82 9, 20.6 mmol) in DMF (20 mL) cooled to 0° C. was added a solution of (4-bromo-2-fluoro-phenyl)-acetonitrile (2.0 g, 9.35 mmol) from Step 1 above, dissolved in THF (10 mL). The reaction was stirred till gas evolution ceased, and then iodomethane (1.3 mL, 20.6 mmol) was added slowly. The reaction was stirred for 30 minutes, and then diluted with 100 mL EtOAc. The solids were removed by filtration, and the organic layer was washed with 100 mL water. The organic layer was dried over MgSO4, and then filtered. The mother liquor was concentrated by rotary evaporation, and the product was distilled under high vacuum (0.3 torr, 45° C.). Yield: 2.25 g, 99%. %. 1H NMR (CDCl3) δ: 2.81 (s, 3H), 2.88 (s, 3H), 7.20-7.25 (m, 3H).
-
- To a solution of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile (3.0 g, 12.4 mmol) in diisopropylamine (32 mL) from step 2 above, and DMF (16 mL) was added racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (3.2 g, 12.4 mmol), PdCl2(PPh3)2 (350 mg, 4 mol %), Cul (71 mg, 3 mol %). The mixture was heated to 90° C. for 30 min before it was cooled down to room temperature. The reaction was diluted with aqueous NH4Cl, extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine, dried with Na2SO4 and evaporated to dryness. The mixture was purified by flash column chromatography (10-50 % EtOAc in hexanes) to give the product (4.2 g, 79% yield). 1H NMR (300 MHz, CDCl3) δ: 1.65-1.76 (m, 14 H), 1.79 (s, 6 H), 1.82-1.85 (m, 1 H), 2.24 (s, 1 H), 2.59 (s, 1 H), 2.67 (m, 2 H), 5.46 (m, 1 H), 7.11 (dd, J=12.15, 1.60 Hz, 1 H), 7.18 (dd, J=8.10, 1.70 Hz, 1 H), 7.45 (t, J=8.10 Hz, 1 H).
-
- To a solution of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile (4.25 g, 10.0 mmol) from step 3 above, in MeOH (100 mL) was added Pd(OH)2 (1.0 g, 20 wt %). The mixture was stirred under H2 for 12 hours before it was filtered through a pad of celite. The solvent was removed and the residue was taken directly into next step without further purification.
- The crude mixture was dissolved in anhydrous MeOH (100 mL) and treated with K2CO3 (2.8 g, 10 mmol). The reaction was heated at 45° C. for 40 min before it was cooled down to room temperature. The crude mixture was diluted with aqueous NH4Cl and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine, dried over Na2SO4. The solvent was removed and the mixture was purified by flash column chromatography (EtOAc in hexanes, 10-40% gradient) to give the desired product (1.4 g, 35% for two steps). 1H NMR (CDCl3) δ: 1.60-1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H).
-
- A solution of glycolic acid (70% in water, 70 mL, 805 mmol) was added to aminoguanidine bicarbonate (55.12 g, 405 mmol) carefully. After foaming subsided, concentrated nitric acid (0.5 mL) was added and the entire reaction was refluxed for 40 hours. The reaction was cooled to 5° C. for 30 minutes, and the solids were filtered. The solids were then triturated with EtOH for 1 hour. The product was then filtered and dried under nitrogen (40.36 g, 52% yield). MS (ESI): 115 (M+H).
-
- To a slurry of (5-amino-1H-[1,2,4]triazol-3-yl)-methanol (9.5 g, 50 mmol) from Step 5 above in acetic acid (200 mL) was added 2,4-pentanedione (5.13 mL, 50 mmol). The mixture was heated to reflux for 4 hours, and then cooled to room temperature. The product was isolated by removing the solvent by rotary evaporation (8.5 g, 95% yield). MS (ESI): 179 (M+H).
-
- A slurry of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol (0.3 g, 1.7 mmol) from Step 6 above and IBX (1.4 g, 5.0 mmol) in 1,2-dichloroethane (22 mL) was stirred at 80° C. for 18 hours. The reaction was cooled to room temperature, and diluted with 100 mL CH2Cl2. After the solids were removed by filtration, the solvent was removed by rotary evaporation to give a yellow solid. The solid was purified by flash chromatography to give the desired product (229 mg, 77% yield). 1H NMR (CDCl3) δ: 2.72 (s, 3H), 2.86 (s, 3H), 6.96 (s, 1H), 10.24 (s, 1H).
-
- The desired product was prepared analogously to example 1, substituting 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. from Step 4 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example.1H NMR (DMSO-d6): δ 0.96 (t, 3H, J=7.4 Hz), 1.30-1.58 (br m, 8H), 1.95 (m, 2H), 2.41 (m, 12H), 2.63 (d,1 H, J =17.5 Hz), 3.61 (d, 1H, J=15.8 Hz), 3.72 (d, 1H, J=15.8 Hz), 6.52 (d, 1H, J=8.1 Hz), 6.74 (m, 2H), 6.93 (s, 1H), 8.84 (s,1 H). Anal. Calcd. For C28H34N4O4.0.5 AcOH: C, 66.90; H, 6.97; N, 10.76. Found: C, 66.89; H, 6.97, N, 10.83.
-
- Sodium hydroxide (1.4 g, 35 mmol) and hydrazine monohydrate (2.04 mL, 42 mmol) were added to a solution of 5′-bromo-2′-hydroxyacetophenone (3 g, 14 mmol) dissolved in triethylene glycol (17 mL). The reaction mixture was heated to 170° C. for 24 h and then partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4and concentrated. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound (2.52 g, 90%).
-
-
- Acetyl chloride (1.06 mL, 14.9 mmol) followed by triethylamine (2.08 mL, 14.9 mmol) were added to a cooled 0° C. solution of 4-Bromo-2-ethyl-phenol (2.5 g, 12.4 mmol, from Step 1 above) dissolved in CH2Cl2. The reaction was stirred for 2 hrs and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4 and concentrated to a brown oil. The oil was purified by silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound as a clear oil (2.44 g, 81%). 1H NMR (CDCl3): δ 1.19 (t, 3H, J=7.7 Hz), 2.32 (s, 3H), 2.52 (q, 2H, J=7.7 Hz), 6.89 (d, 1H, J=8.5 Hz), 7.32 (dd, 1H, J=8.5, 2.2 Hz), 7.38 (d, 1H, J=2.2 Hz).
-
- The title compound was prepared analogously to step 3 in Example lwhere Acetic acid 4-bromo-2-ethyl-phenyl ester from step 2 above, was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. ESIMS: MH+ 373.20, MH− 371.20
-
- A mixture of acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-ethyl-phenyl ester (0.92 g, 2.47 mmol), from step 3 above, potassium carbonate (0.68 g, 4.9 mmol) in MeOH (10 mL) was stirred at rt for 1 h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated to a yellow oil. The oil was purified by silica gel chromatography (20% to 40% EtOAc in hexanes) to give the title compound (2.44 g, 59%). 1H NMR (CDCl3): δ 1.22 (t, 3H, J=7.6 Hz), 1.43-1.78 (br m, 8H), 1.87-2.01 (m, 2H), 2.28 (m, 1H), 2.57-2.63 (m, 4H), 2.76 (s, 2H), 3.42 (s, 2H), 4.63 (s, 1H), 6.68 (d, 1H, J=8.1 Hz), 6.84 (d, 1H, J=8.1 Hz), 6.90 (s, 1H). Anal. Calcd. For C20H26O4.0.25 H2O: C, 71.72; H, 7.98. Found: C, 71.10; H 7.99
-
- The desired product was prepared analogously to example 1, substituting 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (0.24 g, 0.65 mmol) from Step 3 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example. Yield: 64 mg, 19%.1H NMR (CDCl3) δ: 1.25-1.30 (m, 2H), 1.42-1.68 (m, 10H), 1.88-1.93 (m, 2H), 2.30 (p, J=8.59 Hz, 1H), 2.44-2.73 (m, 10H), 4.05 (d, J=3.03 Hz, 2H), 6.76-6.84 (m, 3H), 7.09-7.22 (m, 1H).
-
- To a slurry of sodium hydride (60% dispersion in mineral oil, 0.82 g, 20.6 mmol) in DMF (20 mL) cooled to 0° C. was added a solution of (4-bromo-2-fluoro-phenyl)-acetonitrile (2.0 g, 9.35 mmol) prepared in example 1 (step 1), dissolved in THF (10 mL). The reaction was stirred till gas evolution ceased, and then 1,2-dibromoethane (1.8 mL, 20.6 mmol) was added slowly. The reaction was stirred for 30 minutes, and then diluted with 100 mL EtOAc. The solids were removed by filtration, and the organic layer was washed with 100 mL water. The organic layer was dried over MgSO4, and then filtered. The mother liquor was concentrated by rotary evaporation, and the product was distilled under high vacuum (0.3 torr, 45° C.). Yield: 0.98 g, 44%. 1H NMR (CDCl3) δ: 1.15 (dd, J1=5.31 Hz, J2=2.27 Hz, 2H), 1.48 (dd, J1=5.05 Hz, J2=2.53 Hz, 2H), 6.97-7.12 (m, 3H).
-
- The title compound was prepared analogously to Example 1(step 3), where 1-(4-Bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile from step 1 above, was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. MS (ESI): 422 (M−H).
-
- The title compound was prepared analogously to Example 1(step 4)where 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile from step 2 above, was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile of that example. Yield=0.367 g, 47%.1H NMR (CDCl3) δ: 1.27-1.30 (m, 2H), 1.51-1.73 (m, 10H), 1.84-1.89 (m, 2H), 2.19 (p, J=8.08 Hz, 1H), 2.58-2.71 (m, 4H), 3.36 (d, J=4.04 Hz, 2H), 6.81-6.86 (m, 2H), 7.16-7.18 (m, 1H). MS (ESI): 368 (M−H).
-
- The title compound was prepared analogously to Example 1 where 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde from step 2 below was substituted in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in the final step of that example.1H NMR (400 MHz, CDCl3) δ: 1.48-1.71 (m, 8H), 1.76 (s, 6H), 2.00 (m, 2H), 2.06 (s, 1H), 2.10 (s, 1H), 2.38 (m, 1H), 2.39 (s, 3H), 2.68 (m, 2H), 2.81(m, 1H), 4.09 (s, 2H), 6.86 (d, J=12.9 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 7.84 (t, J=8.1 Hz, 1H), 8.63 (s, 1H), 8.70 (s, 1H). MS (ESI): 518.6(M+H+).
-
- To a solution of (3-amino-1H-1,2,4-triazol-5-yl)methanol (16.6 g, 87.6 mmol) in acetic acid was added 3-ethoxymethacrolein (10.0 g, 87.6 mmol), and the mixture was heated to 80° C. for 4 hours. Upon cooling of the reaction, the product crystallized out of solution. The collected product was a white solid (14.0 g, 92%).1H NMR (300 MHz, DMSO-D6) δ: 2.38 (m, 3 H) 4.63 (m, 2 H) 5.52 (m, 1 H) 8.75 (m, 1 H) 9.21 (m, 1 H). MS (APCI, M+H+): 163.1, 165.1.
-
- A mixture of (6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol(15.7 g, 95.6 mmol) from step 1 above, TEMPO (1.12 mg, 7.2 mmol), and iodobenzene diacetate (33.9 g, 105.2 mmol) in CH2Cl2 (100 mL) was stirred at room temperature for 2 hours. Once the reaction was deemed complete, methyl-tert-butyl ether (50 mL) was added slowly to precipitate the product. The concentrated mother liquor was introduced into a silica gel column and eluted with 2% MeOH/CH2Cl2to give additional amount of the aldehyde product as a while solid (12 g, 80%). 1H NMR (300 MHz, CDCl3) δ: 2.54 (m, 3 H), 8.73 (m, 1 H), 8.85 (m, 1 H), 10.23 (m, 1 H). MS (APCI, M+H+): 163.1.
-
- The desired product was prepared analogously to example 1, substituting (+)-2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile from Step 2 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example.1H NMR (400 MHz, DMSO-d6): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78(d, J=16 Hz, 1H), 3.71(d, J=16 Hz, 1H), 3.84 (d, J=16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1H), 10.88 (s, 1H). Anal. Calcd. For C30H36FN5O3.1.0 H2O: C, 65.56; H, 6.60; N, 12.74. Found: C, 65.50; H, 6.41; N, 12.61. MS(ESI): 532 (M+H)+.
- The desired compound can also be separated from racemic 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile. (100 mg) using chiral HPLC (Chiralpak AS—RH, 150×4.6 mm, 0.6 mL/min, 50% CAN, 50% H2O, 30° C.). (40 mg, 80% recovery, 14.743 min retention time).
-
- To the optically pure (+)-1-cyclopentyl-1-[(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)methyl]prop-2-ynyl ethyl oxalate from Example 42 (step 2), (2.5 g, 15.1 mmol) in 50 ml of MeOH was added K2CO3 (2.0 g). The mixture was stirred at 23° C. for 8 h. After complete conversion, the mixture was neutralized with 1N HCl at cold temperature. The aqueous solution was extracted with MTBE (×3) and the organic layer was washed with brine and dry over MgSO4. After removal of MTBE, 1.75 g of the desired product (+enantiomer) was produced with 95.5% ee and 96% yield.
-
- The title compound was prepared analogously to Example 1 (step 4) where (+)-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one from step 1 above, was substituted in place of racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one in step 3 of that example.1H NMR (CDCl3) δ: 1.60-1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H). MS(ESI):372 (M+H)+.
-
- The desired product was prepared analogously to example 1, substituting 6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione from Step 5 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example.1H NMR (400 MHz, DMSO-d6) δ: 1.12 (t, J=7.3 Hz, 3 H), 1.46-1.75(m, 8 H), 2.14 (m, 2H), 2.44-2.64 (m, 12 H), 2.83 (d, J=17.4 Hz, 1 H), 3.78 (d, J=16.2 Hz, 1 H), 3.88 (d, J=16.2 Hz, 1 H), 6.94 (s, 1 H), 7.05 (s, 1 H), 7.10 (s, 1 H), 6.86 (s, 1 H), 10.90 (s, 1 H). Anal. Calcd. For C28H33N4O4Cl.H2O: C, 61.93; H, 6.50; N 10.32. Found: C, 62.02; H, 6.29; N, 10.13.
-
- Sodium hydroxide (1.2 g, 30 mmol) and hydrazine monohydrate (1.75 mL, 36 mmol) were added to a solution of 5′-bromo-3′-chloro-2′-hydroxyacetophenone (3 g, 12 mmol) dissolved in triethylene glycol (15 mL). The reaction mixture was heated to 160° C. for 72 hours and then partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4and concentrated. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound (2.34 g, 83%). 1H NMR (400 MHz, CDCl3): δ 1.22 (t, J=7.6 Hz, 3 H), 2.65 (q, J=7.6 Hz, 2 H), 5.55 (s,1 H), 7.17 (s, 1 H), 7.31 (s, 1 H).
-
- A solution of 4-Bromo-2-chloro-6-ethyl-phenol (2.3 g, 9.8 mmol) dissolved in THF (10 mL) was added to a cooled 0° C. suspension of NaH (0.43 g, 10.8 mmol, 60% dispersion in mineral oil) in THF (20 ml). After the addition was complete the reaction mixture was warmed up to room temperature and stirred for 30 mins. 2-Methoxyethoxymethyl chloride (1.34 mL, 11.7 mmol) was added and the reaction was stirred for 15 hours. The reaction mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2SO4 and concentrated to a yellow oil. Purification by flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as a clear oil (2.4 g, 76%). 1H NMR (400 MHz, CDCl3): δ 1.21 (t, J=7.3 Hz, 3 H), 2.70 (q, J=7.6 Hz, 2 H), 3.40 (s, 3 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.15 (s, 2 H), 7.24 (s, 1 H), 7.37 (s, 1 H).
-
- A mixture of 5-Bromo-1-chloro-3-ethyl-2-(2-methoxy-ethoxymethoxy)-benzene (1.2 g, 3.6 mmol), 1-Cyclopentyl-2-propen-1-ol (0.5 g, 10.4 mmol), palladium (II) acetate (0.5 mg, 0.05 mol %), and sodium acetate (0.32 g, 4.0 mmol) in N-methylpyrrolidinone (7 mL) was heated to 125° C. under N2 for 4 h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHCO3, brine, dried over Na2SO4 and concentrated to a black oil. The oil was purified by flash column chromatography (0% to 5% EtOAc in hexanes) to give the desired product (0.76 g, 58%). 1H NMR (400 MHz, CDCl3): δ 1.20 (t, J=7.6 Hz, 3 H), 1.54-1.81 (m, 8 H), 2.68 (q, J=7.6 Hz, 2 H), 2.73 (m, 2 H), 2.79-2.85 (m, 3 H), 3.40 (s, 3 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.14 (s, 2 H), 6.90 (d, J=2.0 Hz, 1 H). 7.03 (d, J=2.0 Hz, 1 H).
-
- Methyl acetoacetate (0.67 mL, 6.2 mmol) was added to a cooled 0° C. suspension of NaH (0.25 g, 6.2 mmol, 60% dispersion in mineral oil) in THF (5ml). After 30 min n-BuLi (3.86 mL, 6.2 mmol, 1.6M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 3-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-1-cyclopentyl-propan-1-one (0.76 g, 2.1 mmol) in THF (2 ml). After stirring for 4 h at 0° C., the reaction mixture was quenched with 1N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2SO4 and concentrated to a yellow oil that was used without further purification.
- The oil was dissolved in methanol (10 mL), treated with potassium carbonate (0.85 g, 6.2 mmol), and refluxed under N2 for 2 h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2SO4 and concentrated to a yellow oil that was purified by silica gel chromatography (0% to 30% EtOAc in hexanes) to give the title compound as a gum (0.22 g, 24% yield). 1H NMR (400 MHz, CDCl3): δ 1.21 (t, J=7.6 Hz, 3 H), 1.32-180 (br m, 8 H), 1.92 (m, 2 H), 2.26 (m, 1 H), 2.59 (m, 2 H), 2.69 (q, J=7.6 Hz, 2 H), 2.76 (s, 2 H), 3.40 (s, 3 H), 3.43 (s, 2 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.14 (s, 2 H), 6.86 (s, 1 H), 7.00 (s, 1 H).
-
- Trifluoroacetic acid (0.07 mL, 0.88 mmol) was added to a solution of 6-{2-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl}-6-cyclopentyl-dihydro-pyran-2,4-dione (0.2 g, 0.44 mmol) dissolved in CH2Cl2 (4 mL). The reaction mixture was stirred for 2 hours at room temperature and then partitioned between H2O and EtOAc. The organic extracts were washed with brine, dried over Na2SO4 and concentrated to an oil. The oil was purified by flash column chromatography (0% to 30% EtOAc in hexanes) to give the title compound as a solid. (0.12 g, 75%). 1H NMR (400 MHz, CDCl3): δ 1.21 (t, J=7.6 Hz, 3 H), 1.58-173 (br m, 8 H), 1.92 (m, 2 H), 2.26 (m, 1 H), 2.57 (m, 2 H), 2.65 (q, J=7.6 Hz, 2 H), 2.76 (s, 2 H), 3.43 (s, 2 H). 5.47 (s, 1 H), 6.81 (s, 1 H), 6.95 (s, 1 H). MS: C20H24O4Cl (M−H) 363.10.
-
- A solution of 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile (389 mg, 1.0 mmol) from step 5 below in anhydrous MeOH (4.0 mL) was treated with 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (76.6 mg, 1.30 mmol), followed by borane-dimethylamine complex at room temperature. The reaction was stirred for 12 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with 10% MeOH in CH2Cl2 (3×10 mL) and the combined organic layers were washed with brine, dried over MgSO4. The solvent was removed and the residue was purified by flash column chromatography (80% EtOAc, 14% Hexane, 6% MeOH and 0.5% acetic acid) to give the product (192 mg, 35% yield). 1H NMR (CDCl3) δ: 1.52-1.75 (m, 6 H), 1.83 (s, 3 H), 1.93-1.99 (m, 3 H), 2.09 (s, 3 H), 2.36 (m, 1 H), 2.45 (d, J=7.33 Hz, 1 H), 2 H), 2.60-2.64 (m, 2 H), 2.66 (s, 3 H), 2.72 (d, J=6.06 Hz, 1 H), 2.78 (d, J=7.33 Hz, 1 H), 2.79 (s, 3 H), 4.08 (s, 2 H), 6.68 (d, J=10.86 Hz, 2 H), 6.85 (s,1 H). MS (ESI): 548 (M−H).
-
- A solution of 5-Bromo-2-hydroxymethyl-1,3-difluoro-benzene (0.89 g, 4.0 mmol) and 30 wt % of hydrogen bromide in acetic acid was stirred at room temperature for 90 minutes before it was poured into 80 ml of water. The mixture was extracted with pentane (3×50 ml) and the combined organic layers were washed with water (3×20 ml), dried over MgSO4 and concentrated at low pressure to afford the desired product (10.0 g, 98% yield). 1H NMR (CDCl3) δ: 4.47 (s, 2H), 7.09-7.10 (m, 1H), 7.12-7.13 (m, 1 H).
-
- The desired product was prepared analogously to step 1 in Example 1, substituting 5-Bromo-2-bromomethyl-1,3-difluoro-benzene from step 1 above in place of 4-bromo-1-bromomethyl-2-fluoro-benzene of that example.1H NMR (CDCl3) δ: 3.59 (s, 2H), 7.18 (d, J=6.6 Hz, 2 H).
-
- The desired product was prepared analogously to step 2 in Example 1, substituting (4-Bromo-2,6-difluoro-phenyl)-acetonitrile from step 2 above, in place of (4-bromo-2-fluoro-phenyl)-acetonitrile of that example.1H NMR (CDCl3) δ: 1.87 (s, 6H), 7.13 (d, J=9.3 Hz, 2 H).
-
- The title compound was prepared analogously to Example 1(step 3), where 2-(4-Bromo-2,6-difluoro-phenyl)-2-methyl-propionitrile from step 3 above was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile in that example.1H NMR (CDCl3) δ:1.38-1.48 (m, 4 H), 1.57-1.77 (m, 5 H), 1.85 (s, 6 H), 1.92 (t, J=8.6 Hz, 2 H), 2.25 (m, 1 H), 2.65 (dd, J=15.9, 7.6 Hz, 2 H), 2.75 (dd, J=28.8, 15.7 Hz, 2 H), 3.43 (d, J=4.6 Hz, 2 H), 6.71 (d, J=10.9 Hz, 1 H). MS (ESI): 442 (M−H).
-
- The title compound was prepared analogously to Example 1 (step 4) where 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6-phenyl}-2-methyl-propionitrile from step 4 above, was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl)-2-methylpropanenitrile of that example. Yield=0.367 g, 47%.1H NMR (CDCl3) δ: 1.27-1.30 (m, 2H), 1.51-1.73 (m, 10H), 1.84-1.89 (m, 2H), 2.19 (p, J=8.08 Hz, 1H), 2.58-2.71 (m, 4H), 3.36 (d, J=4.04 Hz, 2H), 6.81-6.86 (m, 2H), 7.16-7.18 (m, 1H). MS (ESI): 368 (M−H).
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 4: Conditions: Chiralpak AS—RH, 150×4.6 mm, 0.6 mL/min, 30° C.; 40% acetonitrile, 60% water, 0.1% formic acid; retention time 24.5 min.
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 4. Conditions: Chiralpak AS—RH, 150×4.6 mm, 0.6 mL/min, 30° C.; 40% acetonitrile, 60% water, 0.1% formic acid; retention time 17.99 min.
-
- A solution of 1-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (568 mg, 1.54 mmol) from step 3 in example 3, in anhydrous MeOH (6.0 mL) was treated with 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (324 mg, 2.0 mmol), (prepared in step 2, example 4), followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour before it was cooled to −10° C. for 2 hours. The precipitate was removed by filtration, and the filtrate was concentrated to an oil. The oil was purified by flash chromatography (50 g SiO2, 1:3→1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder (146 mg, 18%). 1H NMR (400 MHz, CDCl3) δ: 1.41-1.64 (m, 8 H), 1.84-1.88 (m, 2 H), 2.22-2.28 (m, 2 H), 2.42 (s, 3 H), 2.49-2.59 (m, 4 H), 2.65-2.74 (m, 3 H), 3.97-4.05 (m, 2 H), 6.72-6.82 (m, 2 H), 7.05-7.10 (m, 1 H), 8.55 (s, 1 H), 8.67 (s, 1 H).
-
- A solution of 1-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (568 mg, 1.54 mmol) from step 3 in example 3, in anhydrous MeOH (6.0 mL) was treated with [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (296 mg, 2.0 mmol), from step 1 below, followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour and then was concentrated to an oil. The oil was purified by flash chromatography (50 g SiO2, 70% ethyl acetate, 6% methanol, 0.5% acetic acid, 23.5% hexanes) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder (142 mg, 18%). 1H NMR (400 MHz, CDCl3) δ: 1.11-1.18 (m, 2 H), 1.31-1.52 (m, 10 H), 1.75-1.80 (m, 2 H), 2.16 (t, J=8.84 Hz, 1 H), 2.34 (d, J=17.68 Hz, 1 H), 2.46 (t, J=7.83 Hz, 2 H), 2.59 (d, J=17.94 Hz, 1 H), 3.94 (d, J=3.79 Hz, 2 H), 6.62-6.70 (m, 2 H), 6.97 (t, J=7.83 Hz, 1 H), 7.02-7.04 (m, 1 H), 6.82-6.85 (m, 2 H).
-
- The desired product was prepared analogously to step 4 in Example 7 substituting 3-methoxy acrolein, in place of 3-ethoxymethacrolein of that example.
-
- The desired product was prepared analogously to Example 7 substituting 6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, from step 2 below, in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example.1H NMR (CDCl3) δ: 1.57-1.71 (m, 4 H), 1.83 (s, 6 H), 1.94-2.00 (m, 3 H), 2.33-2.40 (m, 2 H), 2.46 (d, J=17.68 Hz, 1 H), 2.65 (t, J=9.09 Hz, 2 H), 2.75 (d, J=18.19 Hz, 2 H), 3.42 (d, J=2.02 Hz, 1 H), 3.75 (t, J=9.35 Hz, 1 H), 4.11 (s, 2 H), 6.68 (d, J=10.86 Hz, 2 H), 8.78 (d, J=2.53 Hz, 1 H), 8.87 (d, J=2.53 Hz, 1 H). MS (ESI): 555 (M−H).
-
- To a slurry of (3-amino-1 H-1,2,4-triazol-5-yl)methanol (28.5 g, 150 mmol) in acetic acid was added chloromalonaldehyde (16 g, 150 mmol). The mixture was heated to 80° C. for 4 hours. Upon cooling of the reaction to room temperature, the product crystallized out as a white solid (25.5 g, 92%).1H NMR (300 MHz, DMSO-D6) δ: 4.67 (s, 2 H), 5.62 (s,1 H), 8.94 (d, J=2.45 Hz, 1 H), 9.81 (d, J=2.45 Hz, 1 H). MS (APCI): 185.0 (M+H+).
-
- A mixture of (6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol (9.86 g, 53.4 mmol), TEMPO (626 mg, 4.01 mmol), iodobenzene diacetate (18.9 g, 58.76 mmol) in CH2Cl2 (75 mL) was stirred at room temperature for 2 hours. Once the reaction was deemed complete, methyl-tert-butyl ether (50 mL) was added slowly to precipitate the product. as a while solid (8.72 g, 90%). 1H NMR (300 MHz, CDCl3) δ: 8.93 (d, J=2.45 Hz, 1 H), 8.99 (d, J=2.64 Hz, 1 H), 10.25 (s,1 H). MS (APCI): 183.0, 185.0 (M+H+).
-
- The desired product was prepared analogously to Example 7, substituting 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (prepared in step 2, example 4) in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example.1H NMR (CDCl3) δ: 1.34-1.40 (m, 2 H), 1.60-1.73 (m, 4 H), 1.83 (s, 6 H), 1.83-1.86 (m, 3 H), 1.93-1.99 (m, 2 H), 2.37 (m, 1 H), 2.42 (d, J=5.56 Hz, 1 H), 2.48 (s, 3 H), 2.64 (t, J=8.34 Hz, 2 H), 2.75 (d, J=17.94 Hz, 1 H), 4.09 (s, 2 H), 6.67 (d, J=11.12 Hz, 2 H), 8.61 (d, J=1.26 Hz, 1 H), 8.69 (d, J=2.27 Hz, 1 H). MS (ESI): 534 (M−H).
-
- A solution of 1-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (568 mg, 1.54 mmol) from step 3 in example 3 in anhydrous MeOH (6.0 mL) was treated with 6-chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (365 mg, 2.0 mmol), prepared in 2 from example 12, followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour and then was concentrated to an oil. The oil was purified by flash chromatography (50 g SiO2, 70% ethyl acetate, 6% methanol, 0.5% acetic acid, 23.5% hexanes). The resultant oil was further purified by flash 50 g SiO2, 1:3→1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder (48.6 mg, 6%). 1H NMR (400 MHz, CDCl3) δ: 1.19-1.24 (m, 2 H), 1.39-1.61 (m, 10 H), 1.83-1.87 (m, 2 H), 2.25 (t, J=8.59 Hz, 1 H), 2.38 (d, J=17.94 Hz, 1 H), 2.54 (t, J=7.71 Hz, 2 H), 2.64 (d, J=17.94 Hz, 1 H), 3.98 (d, J=5.56 Hz, 2 H), 6.71-6.77 (m, 2 H), 7.06 (t, J=7.83 Hz, 1 H), 8.66 (s, 1 H), 8.73 (s, 1 H).
-
- The title compound was prepared analogously to Example 1 where 5-Methyl-3H-imidazole-4-carbaldehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in that example.1H NMR (400 MHz, CDCl3) δ: 1.47-1.71 (m, 8H), 1.70 (s, 6H), 1.88 (m, 2H), 2.12 (s, 3H), 2.28 (m, 1H), 2.43 (d, J=103, 17.4 Hz, 1H), 2.50 (m, 2H), 2.58 (m, 3H), 7.02 (d, J=6.57 Hz, 1H), 7.11 (d, J=13.1 Hz, 1H), 7.34 (t, J=8.6 Hz, 1H), 7.78 (s, 1H). MS (ESI): 467.1 (M+H+).
-
- A solution of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile (200 mg, 0.54 mmol) from step 5 below, in anhydrous MeOH (4.0 mL) was treated with 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (150 mg, 0.86 mmol), followed by borane-dimethylamine complex (47 mg, 0.8 mmol) at room temperature. The reaction was stirred for 5 hours before it was quenched by the addition of 0.5N HCl (25 mL). The mixture was extracted with 10% MeOH in CH2Cl2 (3×10 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by crystallization from EtOAc/Hexanes to give the product as a white solid. 1H NMR (300 MHz, DMSO-d6) δ: 1.64 (m, 8 H), 1.70 (s, 6 H), 2.50 (1, 1 H), 2.57 (s, 3 H), 2.63 (s, 3 H), 2.79 (m, 2 H), 3.77 (m, 2 H), 4.12 (brs, 1 H), 4.50 (m, 1 H), 6.95 (m 3 H), 7.35 (m, 1 H), 10.95 (brs, 1 H).
-
- To a mixture of 1-Bromomethyl-2-fluoro-4-methoxy-benzene (4.5 g, 21 mmol) and Tetrabutylammonium iodide (0.66 g, 2.1 mmol) in CH2Cl2 (50 mL) was added a solution potassium cyanide (4.0 g, 60 mmol) in water (50 mL). The resulting biphasic mixture was stirred vigorously for 8 hours. The reaction was poured into water (100 mL) and extracted with CH2Cl2 (2×50 mL). The organics were washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography (10-30% EtOAc in hexanes) to give the product (2.6 g, 75% yield) as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 3.66 (s, 2 H), 3.82 (s, 3 H), 6.69 (m, 2 H), 7.31 (m, 1 H).
-
- A solution of (2-Fluoro-4-methoxy-phenyl)-acetonitrile, from step 1 above, (5 g, 30 mmol) and lodomethane (6.03 mL, 97 mmol) in DMSO (30 mL) was added drop wise over 2 hours to a stirring solution of KOH (7.47 g, 133 mmol) in water (4 mL) and DMSO (20 mL) at 0° C. The solution was allowed to warm to room temperature and stirred for 4 hours. The reaction was poured into water (100 mL) and extracted with EtOAc (2×50 mL). The organics were washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography (0-10 % EtOAc in hexanes) to give the product (4.76 g, 82% yield) as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.82 (s, 6 H), 3.85 (s, 3 H), 6.64 (d, J=9.6 Hz, 2 H), 7.42 (m, 1 H).
-
- To a solution of 2-(2-Fluoro-4-methoxy-phenyl)-2-methyl-propionitrile, from step 2 above, (1.5 g, 7.8 mmol) in CH2Cl2 (75 mL) at −78 ° C. was added Boron tribromide (1M solution in CH2Cl2) (16 mL, 16 mmol). The solution was allowed to warm to room temperature and stir for 48 hours. The reaction was quenched with 0.5N HCl (50 mL) and poured into water (100 mL). The organic layer was separated and the aqueous was extracted with CH2Cl2 (50 mL). The combined organics were washed with water (100 mL), dried over Na2SO4, filtered and concentrated. The resulting oil was used without further purification.
-
- Potassium carbonate (3.1 g, 22 mmol) was added to a solution of 2-(2-Fluoro-4-hydroxy-phenyl)-2-methyl-propionitrile, from step 3 above, (1.0 g, 6.0 mmol) and 2-Chloro-1-cyclopentyl-ethanone (3.3 g, 22 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 16 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (2×50 mL). The organics were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography (0-15% EtOAc in hexanes) to give the product (1.2 g, 75% yield) as a clear oil. 1H NMR (300 MHz, CDCl3) δ: 1.57-1.93 (m, 14 H), 3.10 (m, 1 H), 4.64 (s, 2 H), 6.65 (d, J=9.6 Hz, 2 H), 7.37 (t, J=8.9 Hz, 1 H).
-
- Sodium hydride (60%) (0.49 g, 12.3 mmol) was magnetically stirred in dry THF (33 mL) and cooled to 0° C. The mixture was then treated with Methyl acetoacetate (1.34 mL, 12.3 mmol) drop wise over 15 min. The reaction was allowed to stir for 30 min at 0° C. To the resulting clear solution was added nBuLi (1.6M in Hexanes) (7.71 mL, 12.3 mmol). The reaction was then allowed to stir for 30 min at 0° C. To the yellow solution was added 2-[4-(2-Cyclopentyl-2-oxo-ethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile, from step 4 above, (1.19 g, 4.1 mmol) as a solution in dry THF (15 mL). The result was stirred at 0° C. for 15 min and then at room temperature for 90 min. The solution was next poured into 0.5N HCl (100 mL) and extracted with EtOAc (2×50 mL). The organics were concentrated and the residue dissolved in MeOH (33 mL) and treated with K2CO3 (1.5 g). The mixture was heated to 65° C. and maintained for 1 hr. The reaction was cooled and poured into 0.5N HCl (100 mL) and extracted with EtOAc (2×50 mL). The organics were dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with CH2Cl2 through 1% MeOH in CH2Cl2 to yield the title compound as a white solid (1.21 g, 79%).
-
-
- A solution of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile from example 16 (step 5), (200 mg, 0.54 mmol) in anhydrous MeOH (4.0 mL) was treated with 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (140 mg, 0.86 mmol), prepared in example 4 (step 2), followed by borane-dimethylamine complex (47 mg, 0.8 mmol) at room temperature. The reaction was stirred for 5 hours before it was quenched by the addition of 0.5N HCl (25 mL). The mixture was extracted with 10% MeOH in CH2Cl2 (3×10 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by crystallization from EtOAc/Hexanes to give the product as a white solid (91 mg, 32% yield). 1H NMR (300 MHz, DMSO-d6) δ: 1.67 (m, 8 H), 1.70 (s, 6 H), 2.38 (s, 3 H), 2.55 (m, 1 H), 2.77 (m, 2 H), 3.77 (m, 2 H), 4.12 (m, 1 H), 4.44 (m, 1 H), 6.97 (m 2 H), 7.35 (m, 1 H), 8.69 (s, 1 H), 9.03 (s, 1 H), 10.98 (brs, 1 H).
-
- The title compound was isolated by chiral chromatography of racemic material described in Step 1 below. Conditions: Chiralpak OJ-RH, 150×4.6 mm, 0.6 mL/min, 30° C.; 35% acetonitrile, 65% water, 0.1% formic acid; retention time 17.6 min.
-
- The title compound was prepared analogously to Example 1 where [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, prepared in step 1 from example 11, was substituted in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in that example.1H NMR (400 MHz, CDCl3) δ: 1.47-1.71 (m, 8H), 1.75 (s, 6H), 2.00 (m, 2H), 2.39 (m, 1H), 2.66 (dd, J=103, 18 Hz, 2H), 2.69 (m, 2H), 4.12 (s, 2H), 6.88 (d, J=12.9 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 7.20 (m, 1H), 7.84 (t, J=8.1 Hz,1H), 8.85 (m, 2H). MS (ESI): 504.1 (M+H+)
-
- The title compound was prepared analogously to Example 1 where 6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde from Example 12 (step 2), was substituted in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in the final step of that example.1H NMR (400 MHz, CDCl3) δ: 1.47-1.71 (m, 8H), 1.75 (s, 6H), 2.00 (m, 2H), 2.39 (m, 1H), 2.65 (dd, J=101, 17.9 Hz, 2H), 2.68 (m, 2H), 4.11 (m, 2H), 6.87 (d, J=11.6 Hz, 1 H), 6.93 (d, J=6.6 Hz, 1H), 7.35 (t, J=8.3 Hz,1H), 8.79 (s, 1H), 8.88 (s, 1H). MS (ESI): 539.1 (M+H+).
-
- The desired product was prepared analogously to Example 7 substituting [1,2,4]Triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example.1H NMR (CDCl3) δ: 1.11 (t, J=7.1 Hz, 2H), 1.49-1.61 (m, 6H), 1.84 (s, 6H), 1.86-1.88 (m, 1H), 1.95-1.99 (m, 1H), 2.40-2.26 (m, 1H), 2.49 (d, J=17.94 Hz, 1H), 2.66 (t, J=8.85 Hz, 2H), 2.77 (d, J=17.69 Hz, 1H), 4.13 (s, 2H), 6.89 (d, J=10.87 Hz, 2H), 7.20 (t, J=6.06 Hz, 1 H), 8.85-8.87 (m, 2H). MS (ESI): 520 (M−H).
-
- The title compound was prepared analogously to Example 1 where imidazo[1,2-a]pyridine-2-carbaldehyde, from step 1 below, was substituted in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in the final step of that example.1H NMR (300 MHz, DMSO-d6) δ: 1.23-1.58 (m, 8H), 1.60 (s, 6 H), 1.82-1.90 (m, 2 H), 2.19-2.29 (m, 2 H) 2.46-2.66 (m, 3 H), 3.50-3.63 (m, 2 H), 6.76 (t, J=6.31 Hz, 1 H), 6.87 (d, J=8.29 Hz, 1 H), 7.12 (m, 3 H), 7.32 (d, J=9.04 Hz, 1 H), 7.51 (s, 1 H), 8.34 (d, J=6.22 Hz, 1 H). Anal. Calcd. For C30H32FN3O3.0.5H2O: C, 70.57; H, 6.51; N, 8.23. Found: C, 70.73; H, 6.55; N, 7.85.
-
- The title compound was prepared as described in J.Heterocycl.Chem.; 1992; 691-697.
-
- The desired product was prepared analogously to example 1, substituting 6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3H)-dione from Step 3 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile and 6-chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, from example 12 (step 2) in place of 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde.1H NMR (300 MHz, DMSO-d6) δ: 1.44 (s, 6 H), 1.52-1.70 (m, 8 H), 1.96-2.10 (m, 2 H), 2.37-2.42 (m, 1 H), 2.55-2.64 (m, 3 H), 2.74-2.80 (m, 1 H), 3.73-3.86 (m, 2 H), 5.17 (s, 1 H), 6.88-6.93 (m, 1 H), 6.99-7.02 (m, 1 H), 7.47-7.52 (m, 1 H), 8.86 (d, J=3.0 Hz, 1 H), 9.58 (d, J=3.0 Hz, 1 H). Anal: calcd for C27H30CIFN4O4.0.9H2O: C, 59.48; H, 5.88; N, 10.28. Found: C, 59.52; H, 5.86; N, 9.90.
-
- A solution of 4-bromo-2-fluorobenzoic acid (10 g) in anhydrous MeOH (200 mL) was added conc. sulfuric acid (0.5 mL). The mixture was heated to reflux for 15 hours before it was cooled down to room temperature. The solvent was removed and the residue was taken up in EtOAc (100 mL) and washed with sat. NaHCO3, brine and dried over Na2SO4. The crude product was taken into next step without further purification.
- To a solution of methyl 4-bromo-2-fluorobenzoate (12 g, 51.5 mmol) in anhydrous ether (140 mL) at 0° C. was added MeMgBr (3.0 M, 70 g) drop wise. The mixture was slowly warmed up to room temperature and stirred for 3 hours. The reaction was quenched by the addition of saturated NH4Cl and extracted with EtOAc (3×150 mL). The combined organic extracts were washed with brine, dried with Na2SO4 and evaporated to dryness. The mixture was purified by flash column chromatography (0-20% EtOAc in hexanes) to give the product (12 g, 95% yield). 1H NMR (300 MHz, CDCl3) δ: 1.62 (s, 6 H), 7.18-7.23 (m, 1 H), 7.25-7.28 (m, 1 H), 7.44-7.49 (m, 1 H).
-
- To a solution of 2-(4-bromo-2-fluorophenyl)propan-2-ol (5.8 g, 25.0 mmol), from step 1 above, in anhydrous NMP (63 mL) was added 1-Cyclopentyl-2-propen-1-ol (3.15 g, 25.0 mmol), NaHCO3 (4.2 g, 50 mmol) and PdCl2(PPh3)2 (350 mg, 2 mol %). The mixture was heated to 140° C. for 4 hours before it was cooled down to room temperature. The reaction was diluted with aqueous NH4Cl, extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine, dried with Na2SO4 and evaporated to dryness. The mixture was purified by flash column chromatography (10-50% EtOAc in hexanes) to give the product (2.5 g, 36% yield). 1H NMR (300 MHz, CDCl3) δ: 1.56-1.82 (m, 8 H), 1.62 (s, 6 H), 2.74-2.78 (m, 2 H), 2.82-2.89 (m, 2 H), 6.84-6.88 (m, 1 H), 6.93-6.95 (m, 1 H), 7.40-7.44 (m, 1 H).
-
- To a solution of methyl acetoacetate (3.9 mL, 36.0 mmol) in anhydrous THF (90 mL) at 0° C. was added NaH (60%, 1.44 g, 36.0 mmol) portionwise. After 10 min, the solution was cooled further to −40° C. n-BuLi (1.6 M, 22.5 mL) was added drop wise and the resulting solution was stirred at that temperature for 30 min. A solution of 1-cyclopentyl-3-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]propan-1-one (2.5 g, 9.0 mmol), from step 2 above, in THF (4 mL) was added and the mixture was slowly warmed up to 25° C. and stirred for 4 hours. The reaction was quenched by the addition of NH4Cl and the mixture was extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine, dried over Na2SO4. The solvent was removed and the crude product was taken directly into next step without further purification.
- The crude product from previous step was dissolved in THF (40 mL) and the solution was treated with 2.0 N NaOH (18 mL). The resulting mixture was stirred at 25° C. for 4 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with EtOAc (3×30 mL) and the combined organic layers were washed with brine, dried over Na2SO4. The solvent was removed and the crude product was purified by column chromatography to give the desired product in 58% yield (two steps). 1H NMR (CDCl3) δ: 1.43-1.77 (m, 8 H), 1.62 (s, 6 H), 1.92-1.99 (m, 2 H), 2.23-2.32 (m, 1 H), 2.64-2.71 (m, 2 H), 2.75-2.78 (m, 2 H), 3.41-3.45 (m, 2 H), 6.81-6.84 (m, 1 H), 6.90-6.92 (m, 1 H), 7.44-7.48 (m,1 H).
-
- The title compound was prepared by using chiral SFC to separate the racemic example Example 10 . Optical rotation determined to be (+).
-
- The title compound was prepared by using chiral SFC to separate the racemic example Example 10 . Optical rotation determined to be (−).
-
- The title compound was prepared by using chiral SFC to separate the racemic example 11. Optical rotation determined to be (−).
-
- The title compound was prepared by using chiral SFC to separate the racemic example 11. Optical rotation determined to be (+).
-
- The title compound was prepared by using chiral SFC to separate the racemic 1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile Example 3: Optical rotation determined to be (−).
-
- A solution of 2-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2 H-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile (272 mg, 0.7 mmol) from step 5 in example 7, in anhydrous MeOH (1.5 mL) was treated with 6-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (324 mg, 2.0 mmol), from step 3 below, followed by borane-dimethylamine complex (191.7 mg, 1.05 mmol) at room temperature. The reaction was stirred for 12 hours. The precipitate was removed by filtration, and the filtrate was concentrated to a crude oil. The crude oil was purified by flash chromatography (25 g SiO2, 1:3:1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid):(81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give product as an oil. It was further purified by preparatory HPLC. Yield: 19.0 mg, 8.0%. 1H NMR (CDCl3) δ: 1.37 (t, J=3.75 Hz, 3H)), 1.48-1.75 (m, 8H), 1.84 (s, 6H), 1,91-2.02 (m, 2H), 2.32-2.49 (m, 3H), 2.61-2.70 (m, 2H), 2.79-2.86 (m, 2H), 4.10 (s, 2H), 6.69 (d, J=10.86 Hz, 2H), 8.62 (s, 1H), 8.73 (s, 1H). MS (ESI): 548 (M−H).
-
- To a slurry of (6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol (5.0 g, 27.09 mmol) from step 1 , example 12, in toluene(100 mL) was added n-Bu3SnCHCH2 (9.45 g, 29.79 mmol) and with catalytic PdCl2(dppf)2 (1.97 g, 10% mmol). The mixture solution was refluxed overnight and then cooled to room temperature. The solution was concentrated and purified by flash chromatography (2% MeOH in CH2Cl2) to give the desired product as light white solid (3.4 g, 71% yield). 1H NMR (300 MHz, CDCl3) δ ppm 4.98 (d, J=6.22 Hz, 2H), 5.60 (m, 1H), 5.92 (m, 1H), 7.75 (m, 1H), 8.59 (d, J=2.26 Hz, 1H), 8.70 (d, J=2.45 Hz, 1H). MS (ESI+), 177 (M+H)
-
- A suspension of the (6-Vinyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol (1.0 g, 5.68 mmol) from step 1 above, and 10% Pd on carbon (200 mg) in MeOH were stirred under an atmosphere of hydrogen for 16 hours. The catalyst was filtered and the solvent was removed in vacuo to afford the desired product (820 mg, 82%) as white solid.1H NMR (300 MHz, CDCl3) δ ppm 1.35 (t, J=7.54, 3H), 2.80 (5.60 (q, J=7.54, 2H), 4.98 (d, J=6.22, 2H), 8.59 (d, J=2.26 Hz, 1H), 8.70 (d, J=2.45 Hz, 1H). MS (ESI+) 179 (M+H)+
-
- The title compound was prepared analogously to Example 12 (step 2), where 6-Ethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol from step 2 above was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile in that example. Product was a white solid (450 mg, 57%).1H NMR (300 MHz, CDCl3) δ ppm 10.25 (s,1H), 8.86 (d, J=2.26 Hz), 8.71(d, J=2.26, 1H) 2.86(q, J=7.54, 2H), 1.45 (t, J=6.22, 3H). MS (ESI+) 177 (M+H)+
-
- A solution of 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile (0.58 g, 1.53 mmol) from step 3 below, in anhydrous MeOH (6 mL) was treated with 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.324 g, 2.0 mmol), from Example 4 (step 2), followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 2 hours, and the solids were filtered away. The organic liquid was concentrated to a thick oil, and then purified by flash chromatography (50 g SiO2, 3:10→3:5 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate/hexanes to give a white powder. 1H NMR (400 MHz, CDCl3) δ: 1.54-1.82 (m, 8H), 2.01-2.13 (m, 3H), 2.38-2.48 (m, 2H), 2.48-2.57 (m, 4H), 2.67-2.77 (m, 4H), 2.82-2.85 (m, 1 H), 2.88 (d, J=6.06 Hz, 2H), 4.19 (s, 2H), 6.92 (dd, J1=11.62 Hz, J2=1.26 Hz, 1H), 6.99 (d, J=8.08 Hz, 1H), 7.17 (t, J=7.96 Hz, 1 H), 8.69 (s, 1 H), 8.78 (d, J=1.52 Hz, 1 H).
-
- A solution of (4-bromo-2-fluoro-phenyl)-acetonitrile (4.0 g, 18.7 mmol) from step 1, example 1 and 1,3-dibromopropane (2.1 mL, 20.6 mmol) in Et2O (5 mL) was slowly added to a slurry of NaH (1.64 g, 41.1 mmol, 60% in mineral oil) in DMSO (19 mL) at room temperature, being careful to keep the temperature below 35 degrees Celsius. The reaction was stirred for 2.5 hours, and then poured into 150 mL of saturated ammonium chloride. To this mixture was added CH22Cl2, and the layers were separated. The aqueous layer was extracted with 2×50 mL of CH2Cl2, and the organic layers were combined. After drying the liquid over MgSO4, the solids were filtered away, and the organic was concentrated to an oil. It was further purified by flash chromatography (90 g SiO2, 1:99→1:20 (EtOAc/Hexanes) to give the desired product (2.81 g, 59%). 1H NMR (400 MHz, CDCl3) δ: 2.06-2.16 (m, H), 2.51-2.63 (m, H), 2.66-2.76 (qd, J=9347 Hz, 2H), 2.86-2.94 (m, 2H), 7.16-7.22 (t, J=8.21 Hz, H), 7.30-7.41 (m, 2H).
-
- The title compound was prepared analogously to Example 1 (step 3), where 1-(4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitrile from step 1 above, was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. MS (ESI): 438.0 (M+H+).
-
- To a solution of 1-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile (6.0 g, 13.7 mmol) from step 2 above was added Pd(OH)2/C (2.0 g) and ethanol (100 mL). The reaction was placed under a nitrogen atmosphere using a balloon filled with hydrogen. The slurry was stirred vigorously for 18 hours. The reaction was filtered to remove all of the solids, and the liquid was concentrated to an oil. The oil was dissolved in methanol (100 mL), and solution of NaOH (1.64 g, 41 mmol) dissolved in water (30 mL). The reaction was stirred for 18 hours, and then acetic acid (1 mL) was added. The liquid was concentrated to an oil, then redissolved in CH2Cl2, and washed with 1 N HCl. The organic layer was dried over MgSO4, filtered, and then concentrated to give the desired product (4.338 g, 83%). MS (ESI): 382 (M−H+).
-
- The desired product was prepared analogously to Example 7, substituting 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl)cyclopropanecarbonitrile from step 3 below, in place of 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile, and 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, prepared in Example 4 (step 2) instead of the 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example. Yield: 18.0 mg, 5.0%.1H NMR (CDCl3) δ: 1.34 (t, J=2.50 Hz, 2H), 1.63-1.74 (m, 9H), 1.81-1.91 (m, 2H), 2.36-2.44 (m, 4H), 2.49 (s, 3H), 2.64-2.74 (m, 4H), 4.10 (s, 2H), 6.70 (d, J=7.4 Hz, 2H), 8.62 (d, J=2.3 Hz, 1H), 8.70 (d, J=2.2 Hz, 1H). MS (ESI): 532 (M−1).
-
- The desired product was prepared analogously to step 1 in example 3, substituting (4-Bromo-2,6-difluoro-phenyl)-acetonitrile prepared in step 2 of example 7 instead of (4-bromo-2-fluoro-phenyl)-acetonitrile of that example. Yield: 1.07 g, 74.4%.1H NMR (CDCl3) δ: 1.36 (t, 2.8 Hz, 2H), 1.77 (t, J=2.7 Hz, 2H), 7.13 (d, J=6.8 Hz, 2H).
-
- The title compound was prepared analogously to Example 1(step 3), where -(4-Bromo-2,6-difluoro-phenyl)-cyclopropanecarbonitrile from step 1 above was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. Yield: 1.20 g, 80.0%.1H NMR (CDCl3) δ: 1.37 (t, J=2.8 Hz, 2H), 1.62-1.70 (m, 6H), 1.72 (s, 3H), 1.73 (s, 3H), 1.74-1.83 (m, 4H), 2.22-2.27 (m, 1H), 2.66 (s, 2H), 5.44 (s, 1H), 6.92 (d, J=8.0 Hz, 2H). MS (ESI): 440 (M−1).
-
- The title compound was prepared analogously to Example 1 (step 4)where 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-cyclopropanecarbonitrile from step 2 above, was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile of that example. Yield: 0.43 g, 42%.1H NMR (CDCl3) δ: 1.35 (t, J=2.8 Hz, 2H), 1.56-1.73 (m, 10H), 1.92 (t, J=4.45 Hz, 2H), 2.21-2.30 (m, 1H), 2.65-2.79 (m, 4H), 3.44 (d, J=5.6 Hz, 2H), 6.71(d, J=8.6 Hz, 2H). MS (ESI): 386 (M−1).
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 13: Condition: ChiralPac AS-H column, 250×4.6 mm, 120 bar, 30% MeOH, 50 mL/min, retention time 4.84 min.
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 13: Condition: ChiralPac AS-H column, 250×4.6 mm, 120 bar, 30% MeOH, 50 mL/min, retention time 2.85 min.
-
- The desired product was prepared analogously to Example 7, substituting 2-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]-2-fluoro-5-methoxy-phenyl}-2-methyl-propionitrile from step 7 below, in place of 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile, and 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde, prepared in step 2 of Example 4, instead of the 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example. Yield: 0.071 g, 16%.1H NMR (CDCl3) δ: 1.54-1.63 (m, 4H), 1.77 (s, 6H), 1.91-1.97 (s, 4H), 2.37-2.45 (m, 1H), 2.48 (s, 3H), 2.57-2.80 (m, 4H), 3.75-3.85 (m, 5H), 4.10 (d, J=5.5 HZ, 2H), 6.84 (d, J=2.1 Hz, 1H), 6.89 (d, 6.6 Hz, 1H), 8.62 (d, J=2.3 Hz, 1H), 8.69 (d, J=2.2 Hz, 1H). MS (ESI): 546 (M−1).
-
- Bromine (15 ml, 300 mmol) was added slowly to a solution of 2-Fluoro-5-methoxy-benzaldehyde (23.12 g, 150 mmol) in chloroform (500 ml), and the mixture was stirred at room temperature for 5 days. The mixture was poured into water (200 ml) and extracted with chloroform (2×200 mL). The organics were washed with water (200 mL) and brine (200 mL), dried over MgSO4, filtered and concentrated. The residue was purified by flash column chromatography (2-16% EtOAc in hexanes) to give the product. Yield: 20.7 g, 60%. 1H NMR (CDCl3) δ: 3.93 (s, 3H), 7.08-7.13 (m, 1H), 7.29 (d, J=12.4 Hz, 1H).
-
- To a solution of 4-Bromo-2-fluoro-5-methoxy-benzaldehyde (4.03 g, 17.33 mmol) from step (1) below in Methanol at 0° C. was added NaBH4 (0.65 g, 17.33 mmol). After the reaction mixture was stirred at 0° C. for 2 hours, it was allowed to warm to room temperature. The organic layer was taken up in ethyl ether, washed with water and dried over MgSO4, filtered and concentrated. The residue was purified by flash chromatography (25-45% EtOAc in hexanes) to give the product. Yield: 3.90 g, 99.0%. 1H NMR (CDCl3) δ: 3.90 (s, 3H), 4.74 (d, J=6.02 Hz, 2H), 6.82 (d, J=6.1 Hz, 1H), 7.29 (d, J=10.58 Hz, 1H).
-
- A solution of (4-Bromo-2-fluoro-5-methoxy-phenyl)-methanol, from step 2 above and 30 wt % of hydrogen bromide in acetic acid was stirred at room temperature for 90 minutes before it was poured into 80 ml of water. The mixture was extracted with pentane (3×50 ml) and the combined organic layers were washed with water (3×20 ml), dried over MgSO4 and concentrated at low pressure to afford the desired product. Yield: 2.45 g, 82.2%. 1H NMR (CDCl3) δ: 3.82 (s, 3H), 4.40 (s, 2H), 6.82 (d, J=5.8 Hz, 1H), 7.24 (d, J=10.58 Hz, 1H).
-
- The desired product was prepared analogously to Example 1 step 1, substituting 1-Bromo-4-bromomethyl-5-fluoro-2-methoxy-benzene from step 3 above in place of 4-bromo-1-bromomethyl-2-fluoro-benzene of that example. Yield: 2.26 g, 99.9%.1H NMR (CDCl3) δ: 3.74 (s, 2H), 3.91 (s, 3H), 6.95 (d, J=6.4 Hz, 1 H), 7.35 (d, J=4.6 Hz,1 H).
-
- The desired product was prepared analogously to Example 1, step 2, substituting (4-Bromo-2-fluoro-5-methoxy-phenyl)-acetonitrile (1.95 g, 8.0 mmol) from step 4 above in place of (4-bromo-2-fluoro-phenyl)-acetonitrile. Yield: 8.72 g, 96.0%.1H NMR (CDCl3) δ: 1.34 (s, 6H), 3.92 (s, 3H), 7.06 (d, J=6.8 Hz, 1H), 7.33 (d, J=10.6 Hz, 1H).
-
- The title compound was prepared analogously to Example 1 (step 3), where 2-(4-Bromo-2-fluoro-5-methoxy-phenyl)-2-methyl-propionitrile from step 5 above was substituted in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. Yield: 8.72 g, 96.0%.1H NMR (CDCl3) δ: 1.50-1.61 (m, 8H), 1.72 (s, 3H), 1.75 (s, 3H), 1.80 (s, 6H), 2.20-2.29 (m, 1H), 2.61 (s, 1H), 2.65 (d, J=9.1 Hz, 2H), 3.87 (s, 3H), 5.53 (s, 1H), 7.00 (d, J=6.5 Hz, 1H, 7.03 (d, J=11.6 Hz, 1H). MS (ESI): 454 (M−1).
-
- The title compound was prepared analogously to Example 1 (step 4)where 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-5-methoxy-phenyl}-2-methyl-propionitrile from step 6 above, was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile of that example. Yield: 0.87 9, 49%.1H NMR (CDCl3) δ: 1.39-1.48 (m, 2H), 1.59-1.68 (m, 5H), 1.79 (s, 6H), 1.83-1.95 (m, 3H), 2.30-2.37 (m, 1H), 2.54-2.69 (m, 4H), 3.83 (s, 3H), 5.30 (s, 1H), 6.86 (d, J=11.9 Hz, 1H), 6.95 (d, J=6.6 Hz, 1H). MS (ESI): 400 (M−1).
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 12: Conditions: ChiralPac AS-H column, 250×20 mm, 110 bar, 30% MeOH, 2.5 mL/min, retention time min.
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 12: Conditions: ChiralPac AS-H column, 250×20 mm, 110 bar, 30% MeOH, 2.5 mL/min, retention time 3.31 min.
-
- The title compound was isolated by chiral chromatography of racemic material described in Example 19: Conditions: ChiralPac AS-H column, 250×20 mm, 110 bar, 30% MeOH, 2.5 mL/min. Optical rotation, determined to be (−)
-
- The title compound was prepared by using chiral SFC to separate the racemic Example 19 Optical rotation determined to be (+).
-
- The title compound is prepared by using chiral SFC to separate the racemic 1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile Example 3:
-
- The title compound was isolated by chiral chromatography of racemic material described in Step 1 from example 18. Conditions: Chiralpak OJ-RH, 150×4.6 mm, 0.6 mL/min, 30° C.; 35% acetonitrile, 65% water, 0.1% formic acid; retention time 21.7 min.
-
- The desired product is prepared analogously to example 1, substituting 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propionitrile in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example.
-
- The desired product is prepared analogously to example 1, substituting 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-cyclopropanecarbonitrile in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile of that example.
- MS (ESI): 512 (M+H).
-
- The desired product was prepared analogously to example 1, substituting (−)-2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile from Step 3 below, in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-fluoro-phenyl}-2-methyl-propionitrile of that example.1H NMR (400 MHz, DMSO-d6): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78 (d, J=16 Hz, 1H), 3.71(d, J=16 Hz, 1H), 3.84 (d, J=16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1 H), 10.88 (s, 1 H). Anal. Calcd. For C30H34FN5O3.0.3 EtOAc: C, 65.15; H, 6,57; N, 12.55. Found: C, 66.86; H, 6.59; N, 12.21. MS(ESI): 532 (M+H)+.
- The desired compound can also be separated from racemic 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile. (100 mg) using chiral HPLC (Chiralpak AS-RH, 150×4.6 mm, 0.6 mL/min, 50% CAN, 50% H2O, 30° C.). (38 mg, 76% recovery, 7.536 min retention time).
-
- To a solution of racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (10 g, 37.9 mmol) in CH2Cl2 (200 ml) was added triethylamine (3.0 eq, 113.7 mmol) at 0° C. Then ethyl chlorooxoacetate (3.0 eq, 113.7 mmol) in CH2Cl2 (10 ml) was added drop wise over a 30-minute period under argon. The solution was allowed to stir overnight at room temperature. After removal of solvent, the crude product was purified using a flash column (heptane: EtOAc, 3:1) to afford the desired oxalate (13.5 g,>95%). API-MS: [M+Na+]: 387;
-
- To a 250 ml three-necked flask equipped with a pH electrode was added 72 ml of phosphate buffer (pH 4.0, 0.5M) andCandida rugosa lipase (5 g, Amano AY). The mixture was stirred vigorously and then the racemic oxalate (from step 1 below, 6 g) in 18 ml of acetonitrile was added. The reaction mixture was allowed to stir at 23° C. and the pH was kept at 4.0 using a pH titrator. The reaction was monitored with HPLC and stopped after 50% conversion (<20 hrs). The mixture was extracted by MTBE (×3) and the combined organic layer was dried over MgSO4. After removal of the solvent, the crude product was separated carefully by silica-gel chromatography, using heptane/EtOAC, which afforded 2.6 g of the oxalate (+enantiomer, 43% yield, 96% ee) and 2.0 g of product (-enantiomer, 46% yield, 92% ee). 1H NMR (300 MHz, CDCl3): δ 1.45-1.80 (m, 8 H), 1,72 (s, 3 H), 1.74 (s, 3 H), 2.13-2.18 (m, 1 H), 2.49 (s,1 H), 2.56 (s, 1H), 2.58 (s, 2 H), 5.43 (s, 1 H).
-
- The title compound was prepared analogously to Example 1 (step 4)where (−)-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one from step 2 above was substituted in place of racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one in step 3 of that example.1H NMR (400 MHz, CDCl3): δ 1.60-1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H).
- Method for determining inhibition of cytochrome P450 2D6: Compounds of interest at 0.3 μM, 1 μM, 3 μM, 10 μM, and 30 μM concentrations, 8 μM dextromethorphan and 1 mM NADPH were incubated with human liver microsomes (0.25 mg/mL protein and 0.075 μM P450) at 37° C. for 20 min. Following the 20 min incubation, the reaction was quenched by addition of 200 μL acetonitrile containing 0.1 μM buspirone as an internal standard. The samples were then vortex mixed and centrifuged to pellet the protein. The supernantant was transferred, dried under nitrogen flow and reconstituted in mobile phase. A 10 uL aliquot was injected onto a gradient reversed phase HPLC system with a Phenomenex Luna C18 (50×4.6 mm) column. Dextrorphan, formed by the metabolism of dextromethorphan by CYP 2D6, was monitored using tandem MS/MS in the APCl mode with the MRM transition of m/z 258.3>156.6. Remaining-CYP2D6 activity (%) was determined for the samples relative to a vehicle control. The data were analyzed by non-linear regression according to % R=% Rmax(1−(C/(C+IC50))) using WinNonLin (version 4.0.1), where % R is the % remaining CYP 2D6 activity relative to the vehicle control, C is the concentration of the compound of interest, and IC50 is the inhibitory concentration of the compound of interest giving 50% inhibition of maximal % remaining activity. The data are reported as IC50s (μM). If more than one assay was performed for a particular compound, the average IC50 is reported with the number of tests in parentheses.
Compound IC50 (μM) 1 0.28(3) 2 1.4 3 <0.074 4 <0.3 5 <0.074 6 0.19 7 <0.074 8 <0.074 9 <0.074 10 <0.074 11 <0.074 12 <0.074 13 <0.074 14 0.27 15 0.72 16 0.2 17 <0.074 18 0.67 19 0.16 20 <0.074 21 0.89 22 0.6 23 0.28 24 1.2 25 1.1 26 0.41 27 0.3 28 0.13 29 1.4 30 0.19 31 0.074 32 0.67 33 <0.074 34 <0.074 35 0.074
Claims (37)
1. A method of increasing the bioavailability in a mammal of a first compound which is metabolized by cytochrome P450, comprising administering to said mammal said first compound and a cytochrome P450-inhibiting amount of a compound of formula (I),
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
2. A method according to claim 1 , wherein the cytochrome P450 is the 2D6 isoform.
3. A method according to claim 1 , wherein said first compound is selected from alprenolol, amiflamine, amitryptyline, aprindine, atomoxetine, bisoprolol, brofaromine, bufuralol, bunitrolol, bupronolol, captopril, chlorpheniramine, chlorpromazine, cilostazol, cinnarizine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, debrisoquine, desipramine, desmethylcitalopram, dexfenfluramine, dextromethorphan, dihydrocodine, dolasetron, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, flunarizine, fluvoxamine, fluoxetine, fluphenazine, guanoxan, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine, methamphetamine, methoxyamphetamine, 5-methoxyindoleethylamine, methoxyphenamine, methylenedioxymethamphetamine, metoprolol, mexiletine, mianserin, minaprine, morphine, nefazodone, nelfinavir, norcodeine, nortryptyline, ondansetron, omeprazole, oxycodone, paclitaxel, paroxetine, perhexiline, perphenazine, phenformin, procodeine, promethazine, N-propylajmaline, propafenone, propanolol, retinoic acid, quinidine, risperidone, ritonavir, RU-486, sparteine, tamoxifen, testosterone, thioridazine, timolol, tolterodine, tomoxatene, tramadol, trazodone, trifluperidol, trimipramine, tropisetron, venlafaxine, vinblastine, and zuclopenthixol..
4. A method of inhibiting cytochrome P450 activity in a mammal, comprising administering to said mammal a cytochrome P450 activity-inhibiting amount of a compound of formula (I),
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
5. A method according to claim 4 , wherein the cytochrome P450 enzyme is the 2D6 isoform.
6. A method of inhibiting cytochrome P450 enzyme activity, comprising contacting said cytochrome P450 enzyme with a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I),
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
7. A method according to claim 6 , wherein the cytochrome P450 enzyme is the 2D6 isoform.
8. A method of decreasing the metabolism in a mammal of a first compound which is metabolized by cytochrome P450 enzyme, comprising administering to said mammal said first compound and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I),
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
9. A method according to claim 8 , wherein the cytochrome P450 enzyme is the 2D6 isoform.
10. A method according to claim 8 , wherein said first compound is selected from alprenolol, amiflamine, amitryptyline, aprindine, atomoxetine, bisoprolol, brofaromine, bufuralol, bunitrolol, bupronolol, captopril, chlorpheniramine, chlorpromazine, cilostazol, cinnarizine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, debrisoquine, desipramine, desmethylcitalopram, dexfenfluramine, dextromethorphan, dihydrocodine, dolasetron, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, flunarizine, fluvoxamine, fluoxetine, fluphenazine, guanoxan, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine, methamphetamine, methoxyamphetamine, 5-methoxyindoleethylamine, methoxyphenamine, methylenedioxymethamphetamine, metoprolol, mexiletine, mianserin, minaprine, morphine, nefazodone, nelfinavir, norcodeine, nortryptyline, ondansetron, omeprazole, oxycodone, paclitaxel, paroxetine, perhexiline, perphenazine, phenformin, procodeine, promethazine, N-propylajmaline, propafenone, propanolol, retinoic acid, quinidine, risperidone, ritonavir, RU-486, sparteine, tamoxifen, testosterone, thioridazine, timolol, tolterodine, tomoxatene, tramadol, trazodone, trifluperidol, trimipramine, tropisetron, venlafaxine, vinblastine, and zuclopenthixol..
11. A method according to claim 1 , wherein in the compound of formula (I):
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2—;
m is an integer from 0 to 3;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
12. A method according to claim 11 , wherein in the compound of formula (I):
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2—;
m is 1, 2or 3;
n is 1;
t is 0, 1, or 2; and
pharmaceutically acceptable salts and solvates thereof.
13. A method according to claim 1 , wherein the compound of formula (I) is selected from those of formula (Ia):
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
14. A method according to claim 1 , wherein the compound of formula (I) is selected from those of formula (Ib):
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
15. A method according to claim 1 , wherein the compound of formula (I) is selected from 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1 2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
16. A method according to claim 1 , wherein the compound of formula (I) is selected from the (R)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1 H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-(2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-(2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
17. A method according to claim 1 , wherein the compound of formula (I) is selected from the (S)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
18. A method according to claim 1 , wherein the compound of formula (I) is substantially enantiomerically pure.
19. A method according to claim 1 , wherein the compound of formula (I) is enantiomerically pure.
20. A composition, comprising a first compound that is metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme activity-inhibiting amount of a compound of formula (I),
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
21. A composition according to claim 20 , wherein said at least one cytochrome P450 enzyme is the 2D6 isoform.
22. A composition according to claim 20 , wherein said first compound is selected from alprenolol, amiflamine, amitryptyline, aprindine, atomoxetine, bisoprolol, brofaromine, bufuralol, bunitrolol, bupronolol, captopril, chlorpheniramine, chlorpromazine, cilostazol, cinnarizine, citalopram, clomipramine, clozapine, codeine, cyclobenzprine, debrisoquine, desipramine, desmethylcitalopram, dexfenfluramine, dextromethorphan, dihydrocodine, dolasetron, donezepil, doxepin, encainide, ethylmorphine, fenfluramine, flecainide, flunarizine, fluvoxamine, fluoxetine, fluphenazine, guanoxan, haloperidol, hydrocodone, imipramine, indoramin, labetalol, lidocaine, loratidine, maprotiline, (R)-methadone, meperidine, methamphetamine, methoxyamphetamine, 5-methoxyindoleethylamine, methoxyphenamine, methylenedioxymethamphetamine, metoprolol, mexiletine, mianserin, minaprine, morphine, nefazodone, nelfinavir, norcodeine, nortryptyline, ondansetron, omeprazole, oxycodone, paclitaxel, paroxetine, perhexiline, perphenazine, phenformin, procodeine, promethazine, N-propylajmaline, propafenone, propanolol, retinoic acid, quinidine, risperidone, ritonavir, RU-486, sparteine, tamoxifen, testosterone, thioridazine, timolol, tolterodine, tomoxatene, tramadol, trazodone, trifluperidol, trimipramine, tropisetron, venlafaxine, vinblastine, and zuclopenthixol..
23. A composition according to claim 20 , wherein in the compound of formula (I):
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2—;
m is an integer from 0 to 3;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
24. A composition according to claim 20 , wherein in the compound of formula (I):
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2—;
m is 1, 2 or 3;
n is 1;
t is 0, 1, or 2; and
pharmaceutically acceptable salts and solvates thereof.
25. A composition according to claim 20 , wherein the compound of formula (I) is selected from those of formula (Ia):
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
26. A composition according to claim 20 , wherein the compound of formula (I) is selected from those of formula (Ib):
wherein:
each R1 is independently selected from fluorine, —C(CH3)2CN, -cyclopropyl-CN, and -cyclobutyl-CN;
each R2 is independently selected from hydrogen, C1-C4 alkyl, and halogen;
X is —CH2— or —O—;
m is an integer from 0 to 5;
n is 1 or 2;
t is an integer from 0 to 3; and
pharmaceutically acceptable salts and solvates thereof.
27. A composition according to claim 20 , wherein the compound of formula (I) is selected from 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
28. A composition according to claim 20 , wherein the compound of formula (I) is selected from the (R)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile, 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
29. A composition according to claim 20 , wherein the compound of formula (I) is selected from the (S)-enantiomers of 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-[2-(3-chloro-5-ethyl-4-hydroxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(4-methyl-1H-imidazol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-({2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}methoxy)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2,6-difluorophenyl)-2-methylpropanenitrile; 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile; 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4triazol[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-3,6-dihydro-2H-pyran-2-yl]ethyl}-2-fluorophenyl)cyclopropanecarbonitrile; 1-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-5-[(6-ethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 1-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]cyclopropanecarbonitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluoro-5-methoxyphenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2,6-difluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 2-[4-(2-{5-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; and pharmaceutically acceptable salts and solvates thereof.
30. A composition according to claim 20 , wherein the compound of formula (I) is substantially enantiomerically pure.
31. A composition according to claim 20 , wherein the compound of formula (I) is enantiomerically pure.
32. A method according to claim 1 ,wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor.
33. A method according to claim 32 , wherein said antagonist of the N-methyl-D-aspartate receptor is (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
34. A method according to claim 8 , wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor.
35. A method according to claim 34 , wherein said antagonist of the N-methyl-D-aspartate receptor is (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
36. A composition according to claim 20 , wherein said first compound is chosen from antagonists of the N-methyl-D-aspartate receptor.
37. A composition according to claim 36 , wherein said antagonist of the N-methyl-D-aspartate receptor is (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, or a pharmaceutically acceptable salt or solvate thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/783,117 US20040224960A1 (en) | 2003-02-21 | 2004-02-17 | Pharmaceutical compositions and methods for their use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44908803P | 2003-02-21 | 2003-02-21 | |
US47235503P | 2003-05-20 | 2003-05-20 | |
US10/783,117 US20040224960A1 (en) | 2003-02-21 | 2004-02-17 | Pharmaceutical compositions and methods for their use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040224960A1 true US20040224960A1 (en) | 2004-11-11 |
Family
ID=32912318
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/718,337 Expired - Fee Related US7148226B2 (en) | 2003-02-21 | 2003-11-19 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
US10/783,117 Abandoned US20040224960A1 (en) | 2003-02-21 | 2004-02-17 | Pharmaceutical compositions and methods for their use |
US11/382,154 Expired - Fee Related US7473790B2 (en) | 2003-02-21 | 2006-05-08 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/718,337 Expired - Fee Related US7148226B2 (en) | 2003-02-21 | 2003-11-19 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/382,154 Expired - Fee Related US7473790B2 (en) | 2003-02-21 | 2006-05-08 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
Country Status (15)
Country | Link |
---|---|
US (3) | US7148226B2 (en) |
EP (1) | EP1597246A2 (en) |
JP (1) | JP3940430B2 (en) |
AR (1) | AR044749A1 (en) |
AU (1) | AU2004213247A1 (en) |
BR (1) | BRPI0407699A (en) |
CA (1) | CA2516235A1 (en) |
IS (1) | IS7896A (en) |
MX (1) | MXPA05007133A (en) |
NL (1) | NL1025544C2 (en) |
PA (1) | PA8596001A1 (en) |
PE (1) | PE20050289A1 (en) |
TW (1) | TW200426143A (en) |
UY (1) | UY28192A1 (en) |
WO (1) | WO2004074270A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080260785A1 (en) * | 2005-09-20 | 2008-10-23 | Dr. Reddy's Laboratories Limited | Paroxetine compositions |
US20080312309A1 (en) * | 2007-05-04 | 2008-12-18 | Cardiome Pharma Corp. | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
US8057811B2 (en) | 2003-07-23 | 2011-11-15 | Douglas Pharmaceuticals Limited | Stable clozapine suspension formulation |
WO2011159920A1 (en) * | 2010-06-17 | 2011-12-22 | Concert Pharmaceuticals, Inc. | [5,6]-dihydro-2h-pyran-2-one derivatives |
CN102336758A (en) * | 2005-08-24 | 2012-02-01 | 辉瑞有限公司 | Compound and combination as HCV polymerase inhibitors |
US8957254B2 (en) | 2009-07-06 | 2015-02-17 | Solvay Sa | Process for chemical synthesis from an alkenone made from a halogenated precursor |
US10449177B2 (en) | 2010-08-19 | 2019-10-22 | Buck Institute For Research On Aging | Methods of treating mild cognitive impairment (MCI) and related disorders |
CN114105745A (en) * | 2020-08-28 | 2022-03-01 | 广东东阳光药业有限公司 | Siponimod intermediate and preparation method thereof |
CN114234210A (en) * | 2021-12-23 | 2022-03-25 | 南通万达锅炉有限公司 | Petrochemical waste liquid integration incineration boiler |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE486600T1 (en) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | DI-ARYL-SUBSTITUTED TETRAZOLE MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR-5 |
ES2361845T3 (en) * | 2004-08-18 | 2011-06-22 | Pfizer, Inc. | RNA POLYMERASE INHIBITORS DEPENDING ON HEPATITIS C VIRUS RNA AND COMPOSITIONS AND TREATMENTS USING THE SAME. |
AR052771A1 (en) | 2004-09-30 | 2007-04-04 | Tibotec Pharm Ltd | HCV INHIBITING BICYCLE PYRIMIDINS |
CN101160285A (en) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists |
BRPI0609650A2 (en) | 2005-03-25 | 2010-04-20 | Tibotec Pharm Ltd | heterobicolytic hvc inhibitors |
AR056347A1 (en) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS |
TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
WO2007010350A1 (en) * | 2005-07-19 | 2007-01-25 | Pfizer Products Inc. | Synthesis of therapeutic diphenyl ethers |
GB0608899D0 (en) * | 2006-05-05 | 2006-06-14 | Leuven K U Res & Dev | Novel viral replication inhibitors |
CN102872461A (en) | 2007-05-04 | 2013-01-16 | 弗特克斯药品有限公司 | Combination therapy for the treatment of hcv infection |
AU2008287421A1 (en) * | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Nitrogen containing bicyclic chemical entities for treating viral infections |
WO2010002428A2 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
WO2010018131A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
KR101649881B1 (en) | 2008-08-11 | 2016-08-30 | 글락소스미스클라인 엘엘씨 | Novel adenine derivatives |
UA103195C2 (en) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
MX2011010058A (en) * | 2009-03-25 | 2011-10-11 | Abbott Lab | Antiviral compounds and uses thereof. |
ES2525826T3 (en) | 2010-02-10 | 2014-12-30 | Glaxosmithkline Llc | 6-Amino-2 - {[(1s) -1-methylbutyl] -oxy} -9- [5- (1-piperidinyl) pentyl] -7,9-dihydro-8H-purin-8-one maleate |
WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
KR20140036269A (en) | 2011-07-01 | 2014-03-25 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
US20150133669A1 (en) | 2012-05-22 | 2015-05-14 | Actelion Pharmaceuticals Ltd. | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
LT3055315T (en) | 2013-10-11 | 2018-10-25 | F. Hoffmann-La Roche Ag | Thiazolopyrimidinones as modulators of nmda receptor activity |
EP3107915B1 (en) | 2014-02-20 | 2017-11-08 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
JP2017533925A (en) | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Adenine derivatives useful for the treatment of allergic diseases or other inflammatory conditions |
EP3283487B1 (en) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyridopyrimidinones and their use as nmda receptor modulators |
JP2018536627A (en) | 2015-09-28 | 2018-12-13 | シンジェンタ パーティシペーションズ アーゲー | Pesticide active heterocyclic derivatives with sulfur-containing substituents |
MA52157A (en) | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | PURINE CYCLIC DINUCLEOTIDES USED AS STING MODULATORS |
CA3008171A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
EP3440072B1 (en) | 2016-04-07 | 2020-01-29 | GlaxoSmithKline Intellectual Property Development Ltd | Heterocyclic amides useful as protein modulators |
CR20200045A (en) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
IL310023A (en) | 2017-06-21 | 2024-03-01 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
EP3746133A1 (en) | 2018-02-02 | 2020-12-09 | Maverix Oncology, Inc. | Novel small molecule drug conjugates of gemcitabine derivatives |
CA3091027A1 (en) | 2018-02-02 | 2019-08-08 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
EP3969438A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
US20220251079A1 (en) | 2019-05-16 | 2022-08-11 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2024028169A1 (en) | 2022-08-01 | 2024-02-08 | Nerviano Medical Sciences S.R.L. | Novel specifically substituted thiophenolic compounds |
CN115784977A (en) * | 2023-02-06 | 2023-03-14 | 淄博新农基作物科学有限公司 | Synthesis process of 2-chloro-3-trifluoromethylpyridine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3786063A (en) * | 1971-05-24 | 1974-01-15 | Universal Oil Prod Co | Thiazolethiosulfonates |
US3904667A (en) * | 1972-04-06 | 1975-09-09 | Du Pont | 4-Halo-2,5-dialkyl-benzeneacetonitriles |
CA1144937A (en) * | 1977-12-22 | 1983-04-19 | Dke J.E. Helgstrand | Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections |
US4326058A (en) * | 1979-02-05 | 1982-04-20 | Sumitomo Chemical Company, Limited | Organo-phosphoric esters and their production and use |
US4489077A (en) * | 1983-03-23 | 1984-12-18 | Warner-Lambert Company | 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides |
US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
EP0773029A4 (en) | 1993-07-19 | 1997-09-03 | Tokyo Tanabe Co | Hepatitis c virus proliferation inhibitor |
US6005103A (en) * | 1993-11-19 | 1999-12-21 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
US5840751A (en) * | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
RU2160733C2 (en) | 1993-11-19 | 2000-12-20 | Парк, Дэвис энд Компани | Pyrone derivatives and pharmaceutically acceptable salts thereof, intermediate compounds for preparation thereof, pharmaceutical composition having antiviral and antibacterial activity based thereon, and method of treating retrovirus- induced infections and diseases |
US5504104A (en) * | 1993-11-19 | 1996-04-02 | Warner-Lambert Company | Tricyclic pyrone derivatives as protease inhibitors and antiviral agents |
CA2176043A1 (en) | 1993-11-19 | 1995-05-26 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
US5834506A (en) * | 1996-11-01 | 1998-11-10 | Warner-Lambert Company | Dihydropyrones with improved antiviral activity |
AU773567B2 (en) * | 1998-09-11 | 2004-05-27 | Warner-Lambert Company | HIV protease inhibitors |
DE19933767B4 (en) | 1999-07-19 | 2013-10-31 | Volkswagen Ag | Fastening arrangement for a windshield wiper system on a vehicle body |
US6512006B1 (en) * | 1999-12-09 | 2003-01-28 | Warner-Lambert Company | HIV protease inhibitors |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
ES2268394T3 (en) * | 2002-04-01 | 2007-03-16 | Pfizer Inc. | INHIBITORS OF PIRANONA AND PIRANDIONA OF THE RNA POLYMERASE DEPENDENT ON THE RNA OF THE VIRUS OF HEPATITIS C. |
DOP2003000641A (en) | 2002-05-10 | 2003-11-15 | Pfizer | INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUSES AND COMPOSITIONS AND TREATMENT USED |
-
2003
- 2003-11-19 US US10/718,337 patent/US7148226B2/en not_active Expired - Fee Related
-
2004
- 2004-02-09 EP EP04709301A patent/EP1597246A2/en not_active Withdrawn
- 2004-02-09 MX MXPA05007133A patent/MXPA05007133A/en not_active Application Discontinuation
- 2004-02-09 WO PCT/IB2004/000493 patent/WO2004074270A2/en not_active Application Discontinuation
- 2004-02-09 BR BR0407699-0A patent/BRPI0407699A/en not_active IP Right Cessation
- 2004-02-09 CA CA002516235A patent/CA2516235A1/en not_active Abandoned
- 2004-02-09 JP JP2006502472A patent/JP3940430B2/en not_active Expired - Fee Related
- 2004-02-09 AU AU2004213247A patent/AU2004213247A1/en not_active Withdrawn
- 2004-02-17 US US10/783,117 patent/US20040224960A1/en not_active Abandoned
- 2004-02-17 PA PA20048596001A patent/PA8596001A1/en unknown
- 2004-02-18 UY UY28192A patent/UY28192A1/en not_active Application Discontinuation
- 2004-02-20 PE PE2004000179A patent/PE20050289A1/en not_active Application Discontinuation
- 2004-02-20 AR ARP040100543A patent/AR044749A1/en unknown
- 2004-02-20 NL NL1025544A patent/NL1025544C2/en not_active IP Right Cessation
- 2004-02-20 TW TW093104282A patent/TW200426143A/en unknown
-
2005
- 2005-06-16 IS IS7896A patent/IS7896A/en unknown
-
2006
- 2006-05-08 US US11/382,154 patent/US7473790B2/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8057811B2 (en) | 2003-07-23 | 2011-11-15 | Douglas Pharmaceuticals Limited | Stable clozapine suspension formulation |
CN102336758A (en) * | 2005-08-24 | 2012-02-01 | 辉瑞有限公司 | Compound and combination as HCV polymerase inhibitors |
US20080260785A1 (en) * | 2005-09-20 | 2008-10-23 | Dr. Reddy's Laboratories Limited | Paroxetine compositions |
US20080312309A1 (en) * | 2007-05-04 | 2008-12-18 | Cardiome Pharma Corp. | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
EP2462933A1 (en) | 2007-05-04 | 2012-06-13 | Cardiome Pharma Corp. | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
EP2468278A1 (en) | 2007-05-04 | 2012-06-27 | Cardiome Pharma Corp. | Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
US8957254B2 (en) | 2009-07-06 | 2015-02-17 | Solvay Sa | Process for chemical synthesis from an alkenone made from a halogenated precursor |
WO2011159920A1 (en) * | 2010-06-17 | 2011-12-22 | Concert Pharmaceuticals, Inc. | [5,6]-dihydro-2h-pyran-2-one derivatives |
US10449177B2 (en) | 2010-08-19 | 2019-10-22 | Buck Institute For Research On Aging | Methods of treating mild cognitive impairment (MCI) and related disorders |
CN114105745A (en) * | 2020-08-28 | 2022-03-01 | 广东东阳光药业有限公司 | Siponimod intermediate and preparation method thereof |
CN114234210A (en) * | 2021-12-23 | 2022-03-25 | 南通万达锅炉有限公司 | Petrochemical waste liquid integration incineration boiler |
Also Published As
Publication number | Publication date |
---|---|
BRPI0407699A (en) | 2006-02-07 |
MXPA05007133A (en) | 2005-08-29 |
PE20050289A1 (en) | 2005-04-29 |
US7148226B2 (en) | 2006-12-12 |
WO2004074270A3 (en) | 2004-12-23 |
JP3940430B2 (en) | 2007-07-04 |
US7473790B2 (en) | 2009-01-06 |
WO2004074270B1 (en) | 2005-03-17 |
IS7896A (en) | 2005-06-16 |
AR044749A1 (en) | 2005-10-05 |
WO2004074270A2 (en) | 2004-09-02 |
EP1597246A2 (en) | 2005-11-23 |
NL1025544A1 (en) | 2004-08-24 |
US20060189681A1 (en) | 2006-08-24 |
CA2516235A1 (en) | 2004-09-02 |
PA8596001A1 (en) | 2004-09-16 |
US20050176701A1 (en) | 2005-08-11 |
NL1025544C2 (en) | 2006-05-09 |
AU2004213247A1 (en) | 2004-09-02 |
TW200426143A (en) | 2004-12-01 |
JP2006518370A (en) | 2006-08-10 |
UY28192A1 (en) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040224960A1 (en) | Pharmaceutical compositions and methods for their use | |
US20230355629A1 (en) | Deuterated derivatives of ruxolitinib | |
JP3418405B2 (en) | Carboline derivative | |
JP2001151778A (en) | Pharmacologically active compound | |
IL191776A (en) | Carbonylamino pyrrolopyrazole compounds , pharmaceutical compositions comprising them and use of the compounds in the preparation of medicaments | |
US6703421B1 (en) | Methods of using phenylmethylbenzoquinone and hydroquinone compounds for treatment of myocarditis, dilated cardiomyopathy and heart failure | |
SK142596A3 (en) | Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use | |
US6537994B2 (en) | Heterocyclic β3 adrenergic receptor agonists | |
EP4089088A1 (en) | Mor receptor agonist compound, preparation method therefor, and use thereof | |
WO2007067817A1 (en) | Abca1 elevating compounds | |
SK7696A3 (en) | 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use | |
US5714487A (en) | 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives | |
EP0724584B1 (en) | Heterocyclic amines having central nervous system activity | |
JP2004528320A (en) | Pharmaceutically active compounds | |
US4469695A (en) | 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives | |
US7943611B2 (en) | Imidazo[1,2-A]pyridin-3-yl-acetic acid hydrazides, processes, for their preparation and pharmaceutical uses thereof | |
JP7090069B2 (en) | Deuterated benzimidazole compounds and their pharmaceutical uses | |
JP2002322162A (en) | Thiazolidine derivative | |
JP2013100235A (en) | Novel indole derivative | |
US20050054669A1 (en) | Process for the synthesis of zolpidem | |
CS241014B2 (en) | Method of 9-aminopyrido-(1,2-a)pyrimidine derivatives production | |
JP2913196B2 (en) | 1,2-ethanediol derivative or salt thereof | |
IE920120A1 (en) | 2,4-DIOXO-PYRIDO[2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS¹AND SALTS THEREOF | |
AU2022249834A9 (en) | Heterocyclic compounds and their use | |
JPH1059950A (en) | 5-phnyl-3-pyridazinone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AGOURON PHARMACEUTICALS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BORCHARDT, ALLEN;DRAGOVICH, PETER SCOTT;GONZALEZ, JAVIER;AND OTHERS;REEL/FRAME:014777/0958;SIGNING DATES FROM 20040506 TO 20040621 Owner name: PFIZER INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BORCHARDT, ALLEN;DRAGOVICH, PETER SCOTT;GONZALEZ, JAVIER;AND OTHERS;REEL/FRAME:014777/0958;SIGNING DATES FROM 20040506 TO 20040621 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |